Category: Treatments & Protocols

Orthobiologic injections, meaning platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC), are offered in selected situations. No one has shown that they can reliably regrow nerve. No one has shown that they reverse peripheral neuropathy or consistently keep it from getting worse. Within the treatment options we have, these injections help patients’ symptoms. They ease pain and numbness and improve day-to-day function.

Here is the evidence behind both of those statements. There are published human studies of orthobiologics in nerve conditions. They are small and short. The way the injections are prepared is not standardized. And much of the work studied people who were screened for being uncomplicated. Saying only “not established” and stopping there leaves something out. It leaves out the part a patient with diabetes and fifteen years of burning feet most needs to hear.

So this page sets out what those studies found and who was in them. It shows who was kept out on purpose. And it shows what a clinician can and cannot honestly conclude from that. This is the talk we have with patients across the St. Louis region, Missouri and Illinois before anything is injected.

Key points

• A 2024 consensus guideline drew on many specialties. It found that “very limited evidence” suggests perineural PRP (PRP injected around the nerve) may improve pain and numbness in diabetic peripheral neuropathy. That was compared with conventional medical management [2].
• A systematic review looked at injectable biologics across nerve pain (neuropathic pain) conditions. It rated the overall certainty of evidence as very low by GRADE criteria [3].
• Every human study of PRP in diabetic peripheral neuropathy that we found added PRP to medical management. None tested it as a stand-alone treatment [4][5].
• These trials, as a rule, exclude diabetes, systemic (whole-body) disease, severe disease and overlapping neuropathies. That covers much of the patient profile this practice actually treats [8][9][10].
• Peripheral neuropathy covers at least seven distinct types, each with its own disease process (pathophysiologic phenotypes) [1]. The driver decides what belongs in a plan.
• Not proven to regrow nerve is not the same as unhelpful. Within the treatment options available, these injections help patients’ symptoms. Both statements carry the same weight here.

First, the condition is not one thing

Burning, numbness and electric sensations are the alarm. They are not the wiring fault. A 2026 review sorts peripheral neuropathy into types (phenotypes). One is distal “dying-back” axonopathy. Others are neuronopathy (ganglionopathy) and demyelinating neuropathies. Then come small-fiber neuropathy and autonomic neuropathy. Next are ischemic, infiltrative or inflammatory axonopathies. Last are focal compressive or entrapment neuropathies [1].

Seven mechanisms, one set of symptom words. That is why a general claim about “injections for neuropathy” is not a claim about anything in particular. It is also why the studies below cannot simply be added together. A trial in carpal tunnel syndrome and a trial in diabetic polyneuropathy are not studying the same disease.

What are PRP and BMAC injections?

PRP is the patient’s own blood. It is drawn and spun in a centrifuge to concentrate platelets and the growth factors they carry. BMAC is bone marrow drawn from the patient. It is then spun to concentrate the mononuclear cell fraction. That fraction includes mesenchymal cells that have not been grown in a lab (culture-expanded).

The 2024 consensus guideline calls these the pillars of regenerative medicine in pain practice. It also notes the rules they fall under. These are Section 361 of the Public Health Service Act and the related federal regulations. Under them, only minimally manipulated products in homologous use (doing the same job in the body) are permitted. Nothing may be added to the product. And it should not have a systemic (whole-body) effect. Growing cells in a lab (culture-expanding) is more than minimal manipulation. It is not permitted on that pathway [2].

That matters for reading claims. A rule that allows a same-day autologous product (made from your own body) is not a finding that the product works. Those two things are easy to blur. Advertising blurs them all the time.

What does the research show about PRP for neuropathy?

The formal guideline position

In 2024, a working group from many specialties published guidelines on regenerative medicine for chronic pain. They are clinical practice guidelines based on evidence. Their Consensus Point 27 covers nerve injections. It says very limited evidence suggests that perineural injection of PRP (PRP injected along certain nerves) may be associated with improvements in pain intensity and in neurological (nerve) symptoms such as numbness. The nerves include the median, ulnar, radial, peroneal, tibial, saphenous and sural nerves. The patients had diabetic peripheral neuropathy. The comparison was conventional medical management [2].

That is the strongest formal statement in this field. And it is hedged on purpose. The same guideline reports on a systematic review. It covered 27 human studies of injectable biologics for nerve pain. The conditions were post-spinal-cord-injury pain, diabetic peripheral neuropathy, painful scars, pudendal neuralgia, trigeminal neuralgia, carpal tunnel syndrome, peripheral neuropathy and radiculopathy. The review found very low certainty of evidence by GRADE criteria [2][3]. Its authors called for a standard preparation, dose and route. They said this must come first, before higher-quality trials could be run [3].

Diabetic peripheral neuropathy: two small studies, both combination designs

The first is a randomized trial of 60 adults with type 2 diabetes. Each had diabetic peripheral neuropathy for at least six months. It ran at a university hospital in Egypt, in its pain clinic and its rheumatology and rehabilitation departments. One group got ultrasound-guided perineural PRP plus medical treatment. The other got medical treatment alone. Patients were checked at one, three and six months. At every visit, pain and numbness scores (visual analog scales) improved more in the PRP group than in the control group. So did the modified Toronto Clinical Neuropathy Score [4].

The honest reading: 60 people, one center, six months. The comparison was PRP plus medication against medication alone. It was not PRP against a sham injection. The full text sits behind a subscription, and we could not verify its exclusion criteria. The published abstract does not state them, and we are not going to guess at them.

The second is a prospective case-control study of 80 people with type 2 diabetic peripheral neuropathy. Of these, 40 got ultrasound-guided perineural PRP with medical treatment. The other 40 got medical treatment alone. At three months in the PRP group, tibial motor nerve conduction velocity (how fast the nerve carries a signal) rose from 38.5 ± 5.2 to 45.3 ± 4.8 m/s. Peroneal motor conduction rose from 36.2 ± 4.9 to 42.7 ± 5.1 m/s. The modified Toronto score fell from 12.4 ± 2.1 to 6.3 ± 1.8. Pain fell from 8.2 ± 1.0 to 3.5 ± 1.2. The control group worsened on both scores over the same period [5].

The honest reading: this was a case-control design, not a randomized one. Participants were not assigned by chance. So a difference between the groups that nobody measured can produce a result like this. Follow-up was three months. This paper is also behind a subscription, and its exclusion criteria could not be verified.

Those two studies hold roughly 140 people between them, at two centers, over three to six months. That is the clinical evidence base for PRP in diabetic peripheral neuropathy that we were able to find. That is not a reason to dismiss them. It is a reason not to build a promise on them.

Bone marrow cells: studied, but not as BMAC and not around the nerve

A 2024 systematic review and meta-analysis screened 5,431 records. It found seven controlled trials of stem cell therapy in diabetic peripheral neuropathy. They covered 400 patients with a mean age of 62.4 ± 8.5 years. Six were done in China in people with type 2 diabetes. One, in Egypt, included both type 1 and type 2. Five used bone marrow-derived mononuclear cells. Two used umbilical cord-derived mesenchymal stromal cells. All but one delivered the cells by intramuscular injection (into muscle) in the leg. The remaining study used intravenous delivery (into a vein) [6].

Pooled results favored treatment. Motor nerve conduction velocity improved by 2.2 m/s (95% CI 1.6 to 2.8). Sensory conduction improved by 1.9 m/s (95% CI 1.1 to 2.6). Vibration perception threshold fell by 2.9 V (95% CI −4.0 to −1.8). The Toronto Clinical Scoring System fell by 3.6 points (95% CI −5.0 to −2.2). Reported complications were pain and swelling at the injection sites, which cleared within days [6].

The honest reading, in the review authors’ own terms: only one of the seven trials was randomized. Four of the seven raised risk-of-bias concerns. Follow-up ran only to 3, 6 or 12 months. And the field lacks high-quality controlled trials with large sample sizes. It also lacks any long-term safety follow-up [6].

There is also a design point that matters directly to a patient asking about an injection. Those cells went into leg muscle, not around a nerve. Bone marrow-derived mononuclear cells are a close relative of BMAC. BMAC is bone marrow aspirate spun to concentrate that same cell fraction [2]. But the preparations are not standardized across studies, and neither is the route. This evidence does not transfer cleanly to a perineural BMAC injection, and we do not present it as though it does. A 2026 review of orthobiologics in type 2 diabetes speaks to this. It states that evidence for BMAC and mesenchymal stromal cell outcomes specifically in diabetic patients remains sparse [11].

Entrapment neuropathy: the best-studied nerve indication, and where its ceiling shows

Carpal tunnel syndrome is a focal compressive neuropathy (one nerve squeezed in one spot). It has more PRP data than any other nerve condition. A 2025 meta-analysis pooled seven randomized trials covering 365 patients. Of these, 183 got PRP and 182 got conventional non-surgical care. All had mild to moderate disease [7].

Symptom severity got better with PRP at one, three and six months. Functional status got better at three and six months. Pain scores were lower at three months but not at one. Meanwhile, the nerve measures showed no statistically significant difference between groups at any time point. Those were the cross-sectional area of the median nerve, sensory nerve conduction velocity and distal motor latency. No serious adverse reactions were recorded in the four studies that tracked them [7].

Both halves of that are true at once. In the nerve condition with the most PRP evidence, what got better was how people felt and functioned. The electrical and ultrasound measurements of the nerve did not follow. Neither half should be dropped when the result is quoted.

A 2025 randomized controlled trial adds a harder finding. It enrolled seventy-five patients with mild to moderate idiopathic carpal tunnel syndrome. Idiopathic means no known cause. They were assigned in equal groups. One got perineural bupivacaine with methylprednisolone. One got pulsed radiofrequency with bupivacaine. One got perineural PRP. All three groups improved in pain, symptoms, function, median nerve cross-sectional area and nerve conduction. Pulsed radiofrequency and steroid produced greater improvement than PRP. The PRP group improved least of the three over the four-month study [8].

That is a modest-to-negative result for PRP, and we are not going to soften it. What we will do is say who was in that trial, because it changes what the result can be used to conclude.

Other nerve conditions: small, and mostly uncontrolled

An open-label interventional study gave a single 1 mL perineural PRP injection to 30 patients. They had Hansen’s disease (leprosy) and ulnar or common peroneal neuropathy. Of those, 27 completed 12 weeks of follow-up. Several things got better. They were two-point discrimination, area of sensory loss, hand dynamometry (grip strength) and foot muscle power. Activity-limitation scores got better at 12 weeks. At 12 weeks, motor nerve conduction amplitude also rose. Sensory latency fell and sensory conduction velocity rose. No adverse effects were recorded beyond one to two days of injection-site pain [9].

There was no control group. This was a single-arm open-label study over 12 weeks. The patients were also on multidrug therapy for the underlying infection. In that setting, treatment effect cannot be separated from natural recovery or expectation. The authors say as much. They also note that long-term effects could not be assessed.

A single-blind randomized comparative trial studied 30 men. Each had an incomplete traumatic sciatic nerve injury. One group got five weekly ultrasound-guided 5 mL perineural PRP injections plus 12 weeks of rehabilitation (rehab). The other got rehab alone. Follow-up lasted six months. At one month, PRP had not improved the motor or sensory function scales. By three and six months, motor function ratings and conduction velocities favored the PRP group over rehab alone. The authors’ own conclusion is that PRP “may be partially effective” in the early repair of incomplete sciatic nerve injuries [10].

Why these studies do not answer the question a complex patient is asking

The people who were screened out

This is the part that decides how much weight any of the above can carry. You can check it in the papers themselves.

Start with the carpal tunnel trial where PRP did worst. In the authors’ words, it excluded “secondary CTS due to systemic disease including thyroid disease, diabetes mellitus, or acromegaly.” It also kept out severe carpal tunnel syndrome. Severe meant any of these: distal motor latency to abductor pollicis brevis above 6.5 ms, absent median sensory potentials, or a nerve cross-sectional area above 15.0 mm². The trial also kept out “other neuropathies overlapping with CTS,” and past median nerve release or wrist surgery. Pregnancy kept people out. So did steroids taken at the same time, and known allergy to the study drugs. So did any carpal tunnel injection in the past six months. Only ages 20 to 60 could enroll. Their disease had to be mild to moderate and idiopathic. It had to have failed at least three months of conservative care [8].

The sciatic nerve trial enrolled only men aged 18 to 60. Each had an incomplete injury three weeks old and no other treatment. The authors state that “patients without other diseases were included,” and they kept out pre-existing bilateral sciatic dysfunction. They also kept out severe cardiopulmonary, hematological, skin, infectious, oncological and psychiatric disorders [10].

The Hansen’s disease study also had a long list. It kept out uncontrolled diabetes mellitus. It kept out known severe cardiac, hepatic or renal disease. It kept out people on antiplatelet drugs. It kept out anyone who took non-steroidal anti-inflammatory drugs within a week. The same went for systemic steroids above 20 mg daily and local steroid injection within six months. It kept out disease found more than three years earlier, and active lepra reactions. It also kept out anyone with a platelet count below 50 × 10³, hemoglobin below 10 g/dL or mean platelet volume above 12.3 fL [9].

The carpal tunnel meta-analysis pooled only mild to moderate disease treated without surgery. Severe disease was not in the pool. Surgical patients were excluded by design [7].

Now read that list against the person who usually walks into this clinic. That person has type 2 diabetes or insulin resistance, and often obesity. They are frequently on an antiplatelet agent (a drug that keeps platelets from clumping). They have ten or twenty years of symptoms and more than one driver at once. They have already tried several treatments without success. Most of them would not have been enrolled in most of these studies.

Two conclusions follow, and they point in opposite directions. Both are true, and we state both.

First, look at a modest or negative result in a screened, uncomplicated group. It does not establish that a treatment fails in the patients who were screened out. That is the usual external-validity problem: results in one group may not hold in another. It is why we do not treat the carpal tunnel finding as a verdict on orthobiologics in metabolic neuropathy.

Second, and just as important, it means the trials did not measure these injections in those patients either. Our position rests on our own clinical use. Within the treatment options available, they help patients’ symptoms. We do not claim they regrow nerve.

What a short single-modality study cannot measure

Every diabetic neuropathy study we found tested PRP added to medical management [4][5]. None tested PRP against a sham. None tested it inside a step-by-step plan that also corrects perfusion (blood flow), blood sugar control and the raw materials repair requires. A study of one treatment cannot report on a combination it never put together.

Follow-up across this entire literature ran from three to twelve months [6][7][8][9][10]. Nothing here speaks to what happens after a year. Peripheral neuropathy is measured in decades.

Outcome measures also disagree with each other. In carpal tunnel, symptoms and function moved while nerve conduction and nerve size did not [7]. In diabetic neuropathy, conduction velocities moved [5]. Those are different questions, and they can truly diverge. A study that measures one is silent about the other. Function is often not measured at all: walking, balance, sleeping through the night.

Efficacy is how well something works in a trial. Effectiveness is how well it works in practice. Those are also different questions. These studies did not standardize preparation protocols, platelet doses, white cell (leukocyte) content, injection volumes, nerve targets or number of sessions. That is exactly what the 2022 systematic review asked the field to fix before running larger trials [3].

Does diabetes make PRP less effective?

There is a complication in this literature that nobody advertises. It deserves stating plainly because it cuts against easy optimism.

A 2026 narrative review looked at orthobiologic therapy in type 2 diabetes. It reports that people with type 2 diabetes respond less to PRP, BMAC and mesenchymal stromal cell preparations. It attributes this to several causes. One is a buildup of advanced glycation end-products. Others are NF-κB-driven chronic inflammation and impaired Nrf2 antioxidant signaling. Still others are mitochondrial dysfunction and lasting epigenetic changes it calls “diabetic memory.” The review also sums up published reports. PRP from donors with diabetes can carry more VEGF (a growth signal) and still give worse clinical results. Bone marrow mobilization failure has been documented at 15.6% in patients with diabetes. In controls without diabetes, the rate was 6.4%. The review says its own framework is hypothesis-generating: it raises ideas to test. It is not a clinical protocol [11].

That is a caution, not a selling point. If metabolic terrain is the rate-limiting step, then treating the terrain is the treatment. Anything injected into unchanged terrain is being asked to do a job the surrounding tissue cannot support. That is one of the reasons metabolic and nutritional care is the foundation here, not an add-on to a procedure.

How evidence strength varies across other options

It helps to see what stronger evidence looks like in the same condition. Take painful diabetic peripheral neuropathy. One randomized trial added 10 kHz spinal cord stimulation to optimized medical management. Responder rates were markedly higher at six months. The benefit held through 24 months [1]. Ultrasound-guided pulsed radiofrequency for focal entrapment-type nerve pain is a different case. Its reported benefits are mostly short to mid-term, with mixed protocols, so certainty varies by indication [1].

The 2026 review that describes both of those calls itself a narrative review. It is not a formal practice guideline [1]. “Described in the literature” and “standard of care” remain different statements. Use the same test with orthobiologics. Ask about the specific phenotype and the specific indication, not about “neuropathy” in general.

What is still unproven about PRP and BMAC for neuropathy?

• No one has shown that orthobiologic injections can reliably regrow nerve, in any type of neuropathy. No one has shown that they reverse peripheral neuropathy. No one has shown that they consistently keep it from getting worse.
• Autologous PRP and same-day BMAC are used under minimal-manipulation, homologous-use rules [2]. That is a regulatory pathway, not a finding that they work.
• We found no head-to-head trial comparing PRP with BMAC in any peripheral neuropathy.
• We found no study of this exact mix. It would test orthobiologics in a length-dependent polyneuropathy, alongside photobiomodulation and metabolic correction. That mix is the only way the question would ever come up here.
• Insurance coverage is a payer decision, not a clinical finding. Patients sign an advance beneficiary notice for non-covered services. Whether something is covered says nothing about whether it works.

What would actually settle the question

A patient has a right to know what a real answer would require. It would take the following, and none of it exists yet.

1. A randomized trial with a credible sham injection, not a group that only gets medication.
2. Trials that enroll people with metabolic dysfunction on purpose. That includes obesity, long-lasting symptoms, many medicines (polypharmacy) and failed past treatment. Plans made in advance to study those subgroups, not exclude them.
3. A standard preparation, fully reported. That means platelet dose, white cell (leukocyte) content, volume, nerve target and number of sessions [3].
4. Outcomes that cover both what patients feel and what can be measured. That matters since symptom scores and nerve conduction have already been shown to move on their own, apart from each other [5][7].
5. Follow-up well beyond twelve months, which nothing in the current literature provides [6].
6. Trials that test the injection inside a combination plan, because a combination is the only setting where it would be used.

What we do instead of guessing

Map the driver before choosing a therapy

Metabolic, nutritional, autoimmune, toxic and structural drivers overlap and often occur together. Finding the dominant one changes what belongs in the plan more than any single treatment does.

The reasoning behind that approach is set out in the science of nerve terrain rehabilitation.

Test to answer a question

We perform electrodiagnostic testing (EMG/NCS) on site. It shows large-fiber involvement and pinpoints where a problem is. It can be normal in small fiber neuropathy, so a normal study does not end the evaluation.

Videonystagmography (VNG) is a diagnostic test of inner-ear balance function. We use it when unsteadiness is part of the picture. It is not a treatment for neuropathy or for anything else.

Treat the terrain the nerve depends on

The foundation comes first. Restore perfusion (blood flow) so oxygen reaches the nerve. Reduce the metabolic pathways that keep causing glycation injury (damage from sugar sticking to tissue). Supply the raw materials repair requires. Class 4 photobiomodulation, class 3B cold laser and whole-body infrared are part of that, matched to the clinical picture.

Qutenza (capsaicin 8% patch) is FDA-approved in adults for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet. It is applied in clinic by a clinician, never dispensed for home use, and repeated no more often than every three months.

What are the downsides of PRP injections?

We do not promise nerve regeneration or reversal of established nerve damage.

We state what is known about safety apart from what is known about benefit. Across this literature, the reported adverse effects were injection-site pain, swelling and bruising that cleared within days [6][7][9][10]. The 2024 consensus panel described PRP and mesenchymal cell products as having minimal injection-related adverse effects, with rare severe reactions [2]. Safety is not efficacy. A treatment can be safe and still not help.

We offer an injection once the workup is finished and the dominant driver has been identified, as one part of the plan, never in place of it. When a service is not covered, we discuss that as a payer decision and document it before anything happens. We do not present it as a comment on whether the treatment works.

“My ethos is to treat all of my patients as I would my own family, with the goal of giving them back their quality of life.” — Dr. Gurpreet Singh Padda, MD, MBA, MHP

Questions worth bringing to the visit

1. Which neuropathy phenotype do you think I have, and what supports that?
2. Which driver is dominant in my case, and how did you establish it?
3. Which parts of this plan are established, and which are less certain?
4. If you are recommending an injection, which study are you relying on, and were patients like me eligible for it?
5. What are we doing about the metabolic terrain, and in what order relative to any procedure?
6. How will progress be measured, and over what period?
7. Do my test results and my symptoms actually agree? If not, what explains the gap?

A clinician who cannot answer the third and fourth questions in plain language is the reason to slow down.

For context on what is used here: Regenerve prepares platelet-rich plasma leukocyte-poor, with no white cells and no red cells. It is activated with calcium chloride. It is made at two to three times baseline platelet concentration, with higher dosing in the six to twelve times range. The target is a measured dose above ten billion platelets per joint.

Frequently asked questions

Are PRP or BMAC injections approved for peripheral neuropathy?

No.Orthobiologic injections are offered in selected situations. Autologous PRP and same-day BMAC are used under federal minimal-manipulation rules. That is a regulatory pathway, not a finding that they work. See the Regenerve Protocol for peripheral neuropathy.

Is there any published research on PRP for diabetic neuropathy?

Yes, but very little. A randomized trial of 60 people reported improvement when PRP was added to medical treatment. So did a non-randomized case-control study of 80 people. Both ran over three to six months. A 2024 consensus guideline calls that “very limited evidence.” Neither study tested PRP on its own against a sham injection. See diabetic peripheral neuropathy treatment in St. Louis.

Why do you say trials may not apply to me?

Because these studies routinely screen out the people this clinic treats. One carpal tunnel trial excluded diabetes, thyroid disease, severe disease and any overlapping neuropathy. A sciatic nerve trial enrolled only men aged 18 to 60 with no other diseases. So a weak result in those groups does not prove failure in complex patients. It also means nobody has shown benefit in them. See the hidden drivers of peripheral neuropathy.

Can an EMG and nerve conduction study confirm small fiber neuropathy?

Not on its own. Nerve conduction studies assess large-fiber function. They can be normal in small fiber neuropathy, so a normal result does not close the question. The symptom pattern still has to be matched to the right test. See small fiber neuropathy symptoms and testing.

Does VNG balance testing treat neuropathy?

No. Videonystagmography is a diagnostic test of inner-ear balance function. It helps tell a vestibular (inner-ear) contribution apart from a nerve contribution when someone is unsteady. It treats nothing. See VNG balance testing.

Does PRP help with neuropathy in the feet?

Within the treatment options we have, PRP helps patients’ symptoms. It eases pain and numbness. It improves day-to-day function. It does not regrow nerve. A 2024 multispecialty guideline found very limited evidence that PRP may improve pain and numbness in diabetic neuropathy, compared with medical management alone. That PRP was injected along nerves, including the tibial, peroneal, saphenous and sural nerves. At Regenerve it is offered in selected situations, once the driver is identified.

Can PRP or BMAC regenerate nerves?

No. No orthobiologic injection has been shown to reliably regenerate nerve. None has been shown to reverse peripheral neuropathy or consistently prevent its progression. We do not claim nerve regrowth. Within the options available, these injections help symptoms. That means less pain and numbness and better function. That is why they sit inside a plan that also treats the metabolic terrain the nerve depends on.

What is the most successful treatment for peripheral neuropathy?

There is no single winner, because peripheral neuropathy covers at least seven different mechanisms. The driver decides what belongs in the plan. Evidence strength also varies by option. For painful diabetic neuropathy, a randomized trial added 10 kHz spinal cord stimulation to medical management. Responder rates were markedly higher at six months. The benefit lasted through 24 months. At Regenerve, mapping the driver comes first.

Next step

Before any injection question is worth asking, the driver has to be identified. Five questions start that map, and it takes a couple of minutes.

Sources

1. Yuba T, Dabbagh A, Sabouri AS. Peripheral neuropathy: a phenotype-driven review for diagnosis and management. Rev Neurol. 2026;81(4):48384. doi:10.31083/RN48384. PMID 42052783. https://pmc.ncbi.nlm.nih.gov/articles/PMC13129557/
2. D’Souza RS, Her YF, Hussain N, et al. Evidence-based clinical practice guidelines on regenerative medicine treatment for chronic pain: a consensus report from a multispecialty working group. J Pain Res. 2024;17:2951-3001. doi:10.2147/JPR.S480559. PMID 39282657. https://pmc.ncbi.nlm.nih.gov/articles/PMC11402349/
3. Bies M, Ashmore Z, Qu W, Hunt C. Injectable biologics for neuropathic pain: a systematic review. Pain Med. 2022;23(10):1733-1749. doi:10.1093/pm/pnac066. PMID 35482528. https://pubmed.ncbi.nlm.nih.gov/35482528/
4. Hassanien M, Elawamy A, Kamel EZ, et al. Perineural platelet-rich plasma for diabetic neuropathic pain, could it make a difference? Pain Med. 2020;21(4):757-765. doi:10.1093/pm/pnz140. PMID 31298289. https://pubmed.ncbi.nlm.nih.gov/31298289/
5. Elsayed AA, Eldeen ES, Osman MA, Elazab SA. Role of platelet rich plasma in management of diabetic peripheral neuropathy: a case-control study. J Ultrasound. 2025. doi:10.1007/s40477-025-01042-7. PMID 40624430. https://pubmed.ncbi.nlm.nih.gov/40624430/
6. Alizadeh SD, Jahani S, Rukerd MRZ, et al. Human studies of the efficacy and safety of stem cells in the treatment of diabetic peripheral neuropathy: a systematic review and meta-analysis. Stem Cell Res Ther. 2024;15(1):442. doi:10.1186/s13287-024-04033-3. PMID 39563393. https://pmc.ncbi.nlm.nih.gov/articles/PMC11577959/
7. Du Y, Jiang X, Fu K, Cui C. Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: a meta-analysis. Medicine (Baltimore). 2025;104(44):e45010. doi:10.1097/MD.0000000000045010. PMID 41261653. https://pmc.ncbi.nlm.nih.gov/articles/PMC12582690/
8. Hashem EY, Shamandy FS, Elmulla AF, Mansour MA. Ultrasound-guided pulsed radiofrequency versus perineural platelet rich plasma injection for the treatment of idiopathic carpal tunnel syndrome: a prospective randomized controlled study. BMC Anesthesiol. 2025;25(1):406. doi:10.1186/s12871-025-03257-x. PMID 40804365. https://pmc.ncbi.nlm.nih.gov/articles/PMC12351916/
9. Saha A, Kothari SY, Sonune S, et al. Effect of single perineural injection of platelet rich plasma on nerve function in Hansen’s disease with truncal neuropathy: an interventional study. Cureus. 2026;18(1):e102127. doi:10.7759/cureus.102127. PMID 41732637. https://pmc.ncbi.nlm.nih.gov/articles/PMC12925252/
10. Yang C, Wang C, Wang C, Yang G, Wu W. The effectiveness of platelet-rich plasma in the treatment of sciatic nerve injury: a single-blind randomized comparative trial. Neural Plast. 2025;2025:7540054. doi:10.1155/np/7540054. PMID 41306443. https://pmc.ncbi.nlm.nih.gov/articles/PMC12646722/
11. Santos MDS, Costa FR, Protasio Netto J, et al. Nutritional interventions to optimize orthobiologic therapy quality in type 2 diabetes mellitus: molecular mechanisms and clinical framework: a narrative review. Int J Mol Sci. 2026;27(9):3749. doi:10.3390/ijms27093749. PMID 42123336. https://pmc.ncbi.nlm.nih.gov/articles/PMC13164227/

The quickest way to tell them apart is timing plus feeling. Plantar fasciitis is usually described as sharp pain under the heel. It is worst with the first few steps out of bed and eases as you warm up. Pressing on the inner heel sets off the pain [2]. Nerve pain in the foot is more often burning, tingling or numbness. It tends to involve the toes and forefoot, and it often gets worse at night instead of better with movement.

Key takeaways

• Location: plantar fasciitis centers on the inner and under side of the heel, where the fascia attaches [2]. Nerve symptoms usually start in the toes and work upward.
• Timing: morning pain on the first steps that improves with movement suggests the fascia [2]. Burning that is worse at rest and at night suggests nerve.
• Feeling: tingling, numbness and electric or hot-coal feelings describe nerves. The fascia does not cause them.
• Both can be present at once. So having one does not close the question.
• A 2013 survey looked at 75,000 US adults aged 18 and older. Of them, 0.85% (95% CI 0.77–0.92) reported diagnosed plantar fasciitis with pain in the past month [1].
• Numbness is a safety problem no matter the cause, because an injury you cannot feel goes untreated.

What does plantar fasciitis feel like?

Plantar fasciitis is a mechanical problem in the tissue that runs along the sole and attaches at the heel. The description clinicians hear most is sharp pain that is worst on the first few steps in the morning or after sitting. It then settles somewhat with activity [2].

On exam, pressing the inner underside of the heel, where the fascia attaches, usually sets off the pain [2]. It is one spot you can find, not a spreading feeling.

It is also common. A 2013 internet panel survey looked at 75,000 US adults aged 18 and older. Of them, 0.85% reported diagnosed plantar fasciitis with pain in the previous month. The reported figures were higher in women than men. They were higher in adults aged 45 to 64 than in younger adults. And they were higher at a BMI of 30 or above than below 25 [1].

What are the first signs of neuropathy in the foot?

Nerve pain reads differently. People describe burning, pins and needles, numbness, or a sense that the foot is padded or not fully theirs. The feelings often do not sit over one spot you can find.

Where it shows up is the other clue. The longest nerve fibers fail first. So symptoms usually begin in the toes and spread upward over time, often in both feet, not one. That is what makes the pattern useful: mechanical pain does not travel that way.

Why is nerve pain in the feet worse at night?

Mechanical pain usually responds to load. It is worse when you use the foot and better when you rest it. Nerve symptoms often do the opposite and are most noticeable when you are still. That is why burning feet at night is such a common complaint.

How do I know if my foot pain is plantar fasciitis or neuropathy?

• Worst moment. Plantar fasciitis: first steps out of bed. Neuropathy: evening and night, at rest.
• Where. Plantar fasciitis: a focal spot at the inner heel. Neuropathy: toes and forefoot, spreading upward, usually both sides.
• Quality. Plantar fasciitis: sharp, mechanical, tied to load. Neuropathy: burning, electric, tingling, numb.
• Response to movement. Plantar fasciitis: eases as you warm up. Neuropathy: mostly unchanged, or worse when you stop.
• Other findings. Plantar fasciitis: none beyond the foot. Neuropathy: often balance changes, less feeling, and symptoms in the hands later.

Use this to describe your symptoms accurately, not to reach a verdict. Mixed pictures are common, and the two can happen together.

Will plantar fasciitis treatment help nerve pain?

Fascia care and nerve care do not overlap much. Months of stretching, orthotics and night splints aimed at a fascia problem will not treat a nerve problem. And the delay costs more than the time.

Neuropathy is a category, not a diagnosis. So finding it is the start of the work, not the end. The next question is which cause is to blame: metabolic, nutritional, autoimmune, toxic or structural.

Numbness changes the urgency

Dulled protective feeling means blisters, burns and pressure injuries can go unnoticed until the skin has broken down. Check both feet daily. Treat an open area or a hot, swollen foot as a reason to be seen, not to wait.

Sudden severe weakness, numbness that gets worse fast, or new loss of bladder or bowel control is an emergency. Go to emergency care, not to a clinic visit.

How the evaluation works at Regenerve

Plantar fasciitis is diagnosed clinically, mostly from the history and from where pressing sets off the pain [2]. Nerve damage needs measuring. We do electrodiagnostic testing (EMG/NCS) on site here.

Conduction studies map the larger fibers. Sometimes the story is burning and temperature change, not numbness and weakness. Then the small fibers are the likely target, and a different check is needed. That is why we also use in-office small-fiber and blood-vessel checks.

What treatment addresses, and what it does not promise

Regenerve offers class 4 photobiomodulation, class 3B cold laser, whole-body infrared, electrodiagnostic testing and metabolic and nutrition care. We apply them as parts of a plan built around the cause we find. Orthobiologic injections such as PRP and BMAC are offered in selected situations.

We do not promise nerve regeneration or reversal. We do not publish success percentages for our protocols.

Frequently asked questions

What is the single fastest way to tell them apart?

Ask what the first steps out of bed feel like. Sharp pain under the heel that is worst on the first few steps and eases as you move is the classic plantar fasciitis description. Burning, tingling or numbness that is worse at night and involves the toes points to nerve damage. See small fiber neuropathy symptoms and testing.

Can I have both at the same time?

Yes. It is common enough that assuming one rules out the other is how people end up treating the wrong problem for months. Mechanical heel pain and nerve symptoms can exist together, and each needs its own answer. See peripheral neuropathy treatments for the feet.

Which test settles it?

No single test covers both. Plantar fasciitis is diagnosed clinically, mostly from where pressing sets off the pain on exam. Nerve damage is checked with electrodiagnostic testing. When the story is burning, not weakness, a small-fiber check is added. See peripheral neuropathy of the feet symptoms.

My balance is off along with the foot pain. Is that related?

It might be a separate problem worth measuring, not part of the foot pain. Videonystagmography is a test of inner-ear balance, used to look into unsteadiness. It is not a treatment for anything. See VNG balance testing.

Where can I be evaluated for this in the St. Louis area?

Addresses, hours and directions are listed on our St. Louis Neuropathy Clinic — Location & Directions page.

Can plantar fasciitis cause numbness in the toes?

Tingling, numbness and electric or hot-coal feelings describe nerves, and the fascia does not cause them. Plantar fasciitis is sharp pain in one spot on the inner underside of the heel. If your toes are numb or tingling, nerve damage is the likely reason, and it can sit alongside heel pain. Numbness is also a safety issue, so check both feet every day.

What is commonly mistaken for plantar fasciitis?

Nerve pain in the foot is often mixed up with it, because both show up on the sole and both can hurt. The difference is the pattern. Fascia pain is sharp, sits at one spot on the inner heel and eases as you warm up. Nerve pain burns or tingles, starts in the toes, spreads upward in both feet and is often worse at rest.

What gets rid of neuropathy in the feet?

Treatment depends on the cause, so the first step is finding it: metabolic, nutritional, autoimmune, toxic or structural. Regenerve builds the plan around that cause using class 4 photobiomodulation, class 3B cold laser, whole-body infrared and metabolic and nutrition care, with PRP or BMAC injections in selected situations. We do not promise nerve regeneration or reversal. And stretching and orthotics aimed at the fascia will not treat it.

Start with the Nerve Damage Score

The starting point at Regenerve is the free five-question Nerve Damage Score. It takes a few minutes. It tells us which cause to look at first, so your visit starts with a plan instead of a guess.

Take the free Nerve Damage Score assessment. Then bring the result to a physician-led visit at Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport. We see patients from the St. Louis region, Missouri and Illinois.

Sources

1. Nahin RL. “Prevalence and Pharmaceutical Treatment of Plantar Fasciitis in United States Adults.” The Journal of Pain, 2018;19(8). doi:10.1016/j.jpain.2018.03.003. https://pmc.ncbi.nlm.nih.gov/articles/PMC6066406/ — referenced for the 0.85% (95% CI 0.77–0.92) of 75,000 US adults aged 18 and older in the 2013 National Health and Wellness Survey who reported diagnosed plantar fasciitis with pain in the past month, and for the reported differences by sex, age band and BMI.
2. Buchanan BK, Sina RE, Kushner D. “Plantar Fasciitis.” StatPearls. StatPearls Publishing; updated January 7, 2024. https://www.ncbi.nlm.nih.gov/books/NBK431073/ — referenced for the first-step morning pain pattern, for pain at the inferior and medial heel reproduced on palpation at the plantar fascial insertion, and for plantar fasciitis being a clinical diagnosis.

If neuropathy balance problems are making you unsteady and raising your falls risk, the useful next step is to find which cause is damaging your nerves. It may be metabolic, nutritional, autoimmune, toxic, or structural. Then match testing and rehab to that cause. Balance depends on accurate feeling coming back from your feet. When that signal fades, ordinary walking gets harder to control. Mapping the cause first is what keeps a falls-prevention plan from turning into guesswork.

Falls are the leading cause of injury for adults ages 65 years and older in the United States. More than 14 million of those older adults, about 1 in 4, report falling every year.¹ Neuropathy is one of the reasons that number stays high.

What we look at first

• Which driver is active. Different causes create different failure patterns, so the plan changes with the cause.
• Metabolic and microvascular strain. When less oxygen reaches the small vessels that feed a nerve, its signals become less reliable.
• Nutritional contributors. Vitamin-related drivers, including B12, can affect both sensation and coordination.
• Toxic and environmental exposures. Heavy metals and other exposures can injure nerves apart from blood sugar.
• Objective testing rather than assumption. We do electrodiagnostic testing (EMG/NCS) on site. It can clarify the nerve pattern.
• Function, not just pain. Steadiness while walking, turning, and stepping down is the result that matters for falls.

Why does neuropathy cause balance problems?

Balance uses several systems at once: feeling from the feet, muscle control, vision, and signals from the inner ear. When peripheral neuropathy dulls that feedback, the brain loses part of its information about how the foot meets the ground.

Many neuropathy causes also injure the fibers that help with timing. That is why unsteadiness in neuropathy is usually not simple weakness. It is the nervous system misreading the ground in real time.

The wiring problem behind numbness and unsteady stepping

Medicine that quiets the signal does not repair the wiring. The alarm keeps ringing because the real problem is still going on. Walking is the moment in the day when that error shows itself.

This is especially true in diabetic peripheral neuropathy. It behaves as a tiny-vessel and metabolic problem that happens to show up in the feet. When blood flow drops, nerves work with less oxygen and send less reliable signals.

How does numbness in the feet lead to falls?

If protective feeling is dulled, a foot can feel normal while pressure, temperature, and position information are all degraded. That mismatch is what turns a small stumble into a fall.

So the goal of treating numbness is not only less burning. It is more accurate information reaching the brain while you walk.

What causes the nerve damage behind balance problems?

Neuropathy is a category, not a diagnosis. Naming the specific cause is what decides which tests are worth doing and what treatment should target.

Diabetic and metabolic drivers

Diabetic neuropathy is rarely a feet-only problem. It usually combines less tiny-vessel blood flow with metabolic damage that affects both nerve function and the coordination of stepping.

A systematic review and meta-analysis published in 2025 pooled 32 studies covering 23,666 older adults with diabetes. It found that 29.5% of that group had fallen.² That is the group in which a talk about balance should start early, not after an injury.

Nutritional drivers, including B12

Vitamin B12 deficiency can affect both feeling and coordination, and it can make burning or numbness worse. When a nutrition cause is present, unsteadiness can get worse faster than the pain does.

That is why diet, digestion, and lab results belong in the workup. Treating the symptom while the cause keeps running does not change the course.

Autoimmune, toxic, and treatment-related contributors

Immune-driven processes can make nerve signals more erratic. That shows up when you change pace, step off a curb, or turn quickly. Chemotherapy is a well-known cause of nerve injury that causes both loss of feeling and timing problems.

Toxic and environmental exposures can damage nerves and small vessels as well. When the exposure history fits, it belongs in the cause map with everything else. Several of these are covered in our review of the neuropathy drivers that are most often missed.

When the label says idiopathic

“Idiopathic” does not mean no cause. It often means the workup did not find the active one. Mixed cases are common, such as metabolic plus nutritional, or autoimmune plus structural.

If you have been told nothing can be done about the cause, that is a reason to recheck the cause map, not a reason to stop.

How are neuropathy balance problems tested?

When someone comes in worried about falling, the first question is not which medicine they take. It is which cause is active, and what failure of function it is causing.

On-site electrodiagnostic testing

We do electrodiagnostic testing (EMG/NCS) on site at Regenerve. It can help show which nerves are involved and what pattern is present. Those findings guide decisions, so the plan does not rest on a symptom description alone.

VNG balance testing is diagnostic, not a treatment

VNG (videonystagmography) checks inner-ear balance. It is a test, never a treatment. Its value here is separating an inner-ear cause from a nerve cause.

Unsteadiness often has more than one cause in older adults. That separation is what keeps the plan from targeting the wrong system.

Small-fiber and autonomic contributors

Small fiber damage can cause burning and hot-coal feelings. It can also affect autonomic function, the body’s automatic controls. When those signals are involved, blood pressure control can shift. That changes how steady you are when standing and turning.

How treatment and rehabilitation fit together

Treatment has to do two things at once. It has to cut the injury still being done to the nerve. And it has to support the function that keeps you upright.

In-clinic modalities

Class 4 photobiomodulation, class 3B cold laser, and whole-body infrared are offered in clinic as part of a wider, cause-based plan. We do not present them as nerve regeneration, reversal, or a cure. We do not publish a success rate for them.

Orthobiologic injections and the honest framing

Orthobiologic injections (PRP and BMAC) are offered here. Nothing about them should be described as a repair of nerve injury.

Metabolic and nutritional care matched to the driver

Metabolic and nutrition care is built around whichever cause is active. That is why the same symptom can lead to two different plans. The point is to stop the ongoing injury while we work on function.

How can you lower your risk of falling with neuropathy?

• Remove trip hazards and keep lighting consistent, especially on the route you walk at night.
• Wear supportive shoes and avoid going barefoot when protective feeling is dulled.
• Slow down your turns and changes in position, especially when standing up from sitting.
• Check your feet often, since dulled feeling means an injury may not make itself known.

Where we are and how to start

Regenerve is located at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport, and we see patients from across the St. Louis region, Missouri and Illinois. You can call (314) 886-5739 or text (314) 886-5902, or email info@regenerve.com.

The free Nerve Damage Score is a five-question starting point. It helps sort out the cause question before your visit. Bring the result with you, and we will build the workup around it.

Family members who help at home will find practical steps in our caregiver guide to peripheral neuropathy.

Frequently asked questions

Can balance problems from neuropathy be caused by something other than diabetes?

Yes. Balance trouble can follow a nutrition cause, an autoimmune process, a toxic exposure, chemotherapy, or a structural problem. More than one can be active at once. That is why we map the cause instead of assuming diabetes is the only one. See how a “normal” B12 can still be a driver.

Does VNG balance testing treat my dizziness?

No. VNG (videonystagmography) is a test of inner-ear balance, not a treatment. It is useful when you have both numbness and dizziness. It helps separate an inner-ear cause from a nerve cause. See what VNG balance testing measures.

Can class 4 photobiomodulation or cold laser fix my balance?

Neither is a balance treatment, and we do not present them as nerve regeneration or reversal. They are in-clinic treatments we may use alongside cause-based metabolic and nutrition care. Any balance benefit would come from the overall plan, not the device. See the treatments we offer.

I have burning feet at night as well as unsteadiness. Are those related?

They can be. Burning and dulled feeling both come from the same nerve terrain. Small-fiber damage can also affect the automatic control of blood pressure. That changes how steady you feel when you stand or turn. See small fiber neuropathy symptoms and testing.

I was told my neuropathy is idiopathic. Is there anything left to check?

Often yes. “Idiopathic” means no cause was found, not that no cause exists. Mixed cases are common. We reopen the cause map so the balance plan is built on a cause, not a label. See the drivers that are commonly missed.

Can neuropathy affect your ability to walk?

Yes. Walking depends on accurate feeling from your feet. Neuropathy dulls that signal, so the brain misreads how the foot meets the ground. The trouble usually shows up when you turn, change pace, step down or step off a curb. When small fibers affect blood pressure control, standing up and turning can feel less steady too.

Why do I feel off balance but not dizzy?

Balance draws on feeling from the feet, muscle control, vision and the inner ear. Neuropathy can take away part of the foot signal without causing any spinning. So you feel unsteady, not dizzy. When both are present, VNG testing of the inner ear helps separate an inner-ear cause from a nerve cause, so the plan targets the right system.

What is the best thing to do about neuropathy and balance?

Find out which cause is damaging the nerves first: metabolic, nutritional, autoimmune, toxic or structural. That decides which tests are worth doing and what treatment should target. In the meantime, remove trip hazards and keep lighting steady on your night route. Wear supportive shoes instead of going barefoot. Slow your turns and check your feet often.

Sources

1. Centers for Disease Control and Prevention. Older Adult Falls Data. https://www.cdc.gov/falls/data-research/index.html (falls as the leading cause of injury, and more than 14 million adults ages 65 and older in the United States reporting a fall each year).
2. Journal of the American Medical Directors Association. Prevalence and Risk Factors for Falls in Older Adults With Diabetes: A Systematic Review and Meta-Analysis. 2025. https://www.jamda.com/article/S1525-8610(25)00529-8/fulltext (pooled falls prevalence of 29.5% across 32 studies and 23,666 older adults with diabetes).

Yes, thyroid function can affect peripheral nerves, and it can do so before anyone uses the word neuropathy. One study compared 60 adults aged 20 to 50 with newly diagnosed hypothyroidism against 60 healthy people of the same ages. Nerve conduction testing showed statistically significant changes across motor and sensory nerves. Signals took longer to start (latency), and speed and strength (velocity and amplitude) dropped [1]. That does not mean your thyroid explains every symptom you have. But it does mean thyroid function belongs on the list of causes you check.

Key takeaways

• Hypothyroidism has been associated with measurable nerve conduction changes in adults with newly diagnosed disease [1].
• Peripheral neuropathy is a category, not a diagnosis. The useful question is which cause is doing the damage: metabolic, nutritional, autoimmune, toxic or structural.
• Genetic evidence in people of European ancestry links hypothyroidism to higher odds of diabetic peripheral neuropathy. It did not show the same direction of effect for every type of neuropathy studied [2].
• Thyroid disease and metabolic disease often come together. So finding one cause is not a reason to stop looking.
• We do electrodiagnostic testing (EMG/NCS) on site at Regenerve. That way symptoms can be matched to measured nerve function, not to a label.

How does low thyroid affect your nerves?

Peripheral nerves are tissue that needs a lot of energy. They depend on a steady oxygen supply through very small blood vessels and on steady energy handling inside the cell. Thyroid hormone affects both.

When thyroid hormone is low, that background shifts. The change is often subtle at first. That is why nerve testing can be abnormal before a person describes a clear pattern of numbness or burning.

None of this makes hypothyroidism the automatic answer for foot symptoms. It makes thyroid status one of several things worth confirming before a workup is called complete. If you want the wider list, read about the hidden drivers of peripheral neuropathy.

What does nerve testing show in people with hypothyroidism?

The 2016 study in Annals of Medical and Health Sciences Research tested 60 adults aged 20 to 50 with recently diagnosed hypothyroidism against 60 healthy people of the same ages. In the motor nerves examined, the hypothyroid group showed significantly increased latencies and decreased conduction velocities [1].

The sensory nerves tested, median and sural, showed the same direction of change: longer latencies with lower velocities and amplitudes [1]. The authors concluded that nerve involvement can develop at an early stage of hypothyroidism.

Two limits are worth stating plainly. This was a single study in adults aged 20 to 50. And abnormal conduction numbers are not the same thing as disabling symptoms.

Does hypothyroidism raise the risk of diabetic neuropathy?

A 2024 Mendelian randomization study in Frontiers in Endocrinology looked at eight nerve conditions using genetic data from people of European ancestry. It reported that genetically predicted hypothyroidism was associated with increased odds of diabetic peripheral neuropathy, with an odds ratio of 1.22 [2].

The same analysis did not point the same way for every type. For polyneuropathies the estimate ran in the protective direction. That is a reminder that neuropathy subtypes do not behave as one disease [2].

Read this as a signal about risk, not as proof that treating a thyroid lab will resolve nerve pain. It supports checking thyroid status carefully when diabetes and nerve symptoms are both present, alongside the blood sugar work that drives diabetic nerve damage.

Neuropathy is a category, so the work is finding the driver

Treating “neuropathy” as though it were one disease is the most common way a workup stalls. The groups below are what we sort symptoms into before choosing tests.

Driver categories we evaluate

• Metabolic, including diabetes, prediabetes and thyroid disease.
• Nutritional, including B12 status and malabsorption after surgery.
• Autoimmune and inflammatory, when the pattern suggests the immune system is attacking nerve.
• Toxic, including medicine effects, alcohol and heavy metal exposure.
• Structural, including trapped nerves and spine-related causes.

More than one of these is often active at once. That is the practical reason we map before we treat.

How is neuropathy tested when you have thyroid disease?

Testing exists to separate three different problems. One is slowed conduction in the large nerve fibers. Another is injury to the small fibers. The third is a nerve environment that is short on oxygen or under metabolic strain. Each one points somewhere different.

Electrodiagnostic testing (EMG/NCS) on site

Electrodiagnostic testing measures how well the larger nerves conduct. It shows whether the pattern fits a neuropathy that hits the longest nerves first, a trapped nerve or something else. At Regenerve we do this on site instead of sending you elsewhere.

Small-fiber and vascular assessment

Burning, temperature changes and pain that seems out of proportion to the exam often involve the small fibers. Standard conduction studies do not capture those. We use in-office checks of small-fiber and blood-vessel function, so the plan is built on measurement.

What care looks like when the driver is metabolic or endocrine

Thyroid replacement is managed by the clinician who prescribes it. Our work sits alongside that. It aims at the environment around the nerve, not at masking the signal.

In-clinic modalities we offer

Regenerve offers class 4 photobiomodulation, class 3B cold laser and whole-body infrared as parts of a plan, applied in clinic under clinician direction. They support the tissue environment while the cause we found is treated. They are not stand-alone answers.

What we do not claim

We do not promise nerve regeneration or reversal. We do not publish success percentages for our protocols. What we can commit to is measuring before treating and telling you what the measurements show.

Frequently asked questions

Can hypothyroidism cause peripheral neuropathy?

Low thyroid function has been linked to measurable changes in nerve conduction. One study compared 60 adults aged 20 to 50 with newly diagnosed hypothyroidism against 60 healthy people of the same ages. Their motor and sensory nerves showed longer latencies and slower conduction velocities than the healthy group. That is a reason to test instead of assume, because more than one cause is often present. See peripheral neuropathy of the feet symptoms.

I have hypothyroidism and burning feet at night. What testing should I ask about?

Burning that is worse at night often points to the small nerve fibers, which standard nerve conduction testing does not measure well. A useful workup separates large-fiber conduction from small-fiber and autonomic function. It also checks for nutrition and toxic causes at the same time. See small fiber neuropathy symptoms and testing.

Does thyroid disease change how diabetic neuropathy is managed?

It can change what gets looked at. A 2024 Mendelian randomization study in people of European ancestry reported that genetically predicted hypothyroidism was associated with higher odds of diabetic peripheral neuropathy. So thyroid status is worth confirming when both conditions are in play. The metabolic work does not change. See diabetic peripheral neuropathy treatment in St. Louis.

If my thyroid labs are treated and my feet still burn, what then?

That is common. It usually means thyroid function was one cause, not the only one. The next step is to look for nutrition, toxic, autoimmune and structural causes instead of repeating the same lab. See functional B12 deficiency and neuropathy.

What does hypothyroid neuropathy feel like?

Often it feels like very little at first. The change can be subtle. Nerve testing can turn abnormal before a person notices a clear pattern of numbness or burning. When symptoms do show up, burning, temperature changes, and pain that seems out of proportion to the exam often point to the small nerve fibers. Standard conduction studies do not capture those. That is why testing matters more than the label.

Is hypothyroid neuropathy reversible?

No one should promise that. Regenerve does not promise nerve regeneration or reversal, and it does not publish success rates. Research shows nerve involvement can begin early in hypothyroidism. And abnormal conduction numbers are not the same as disabling symptoms. The useful work is to measure nerve function on site and leave thyroid replacement to the clinician who prescribes it. Then check the other causes that often come with it: metabolic, nutritional, autoimmune, toxic, and structural.

How is thyroid neuropathy treated?

Thyroid replacement is managed by the clinician who prescribes it. Care at Regenerve sits alongside that and targets the environment around the nerve. Class 4 photobiomodulation, class 3B cold laser, and whole-body infrared are applied in the clinic as parts of a plan, not as stand-alone answers. Before any of that, on-site EMG and nerve conduction testing, plus small-fiber and blood-vessel checks, show which cause to treat first.

Start with the Nerve Damage Score

The starting point at Regenerve is the free five-question Nerve Damage Score. It takes a few minutes. It tells us which cause to look at first, so your visit starts with a plan instead of a guess.

Take the free Nerve Damage Score assessment. Then bring the result to a physician-led visit at Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport. We see patients from the St. Louis region, Missouri and Illinois.

Sources

1. Gupta N, Arora M, Sharma R, Arora KS. “Peripheral and Central Nervous System Involvement in Recently Diagnosed Cases of Hypothyroidism: An Electrophysiological Study.” Annals of Medical and Health Sciences Research, 2016;6(5). https://pmc.ncbi.nlm.nih.gov/articles/PMC5414436/ — referenced for the nerve conduction findings in 60 adults aged 20 to 50 with newly diagnosed hypothyroidism versus 60 age-matched healthy controls.
2. Frontiers in Endocrinology. “Causal relationship between hypothyroidism and peripheral neuropathy: a Mendelian randomization study of European ancestry.” 2024. doi:10.3389/fendo.2024.1436823. https://pmc.ncbi.nlm.nih.gov/articles/PMC11631618/ — referenced for the odds ratio of 1.22 for diabetic peripheral neuropathy in people of European ancestry and for the differing direction of effect across neuropathy phenotypes.

“Idiopathic” peripheral neuropathy does not mean nothing can be found. It means the workup that was done did not find a cause. One chart review looked at 284 patients sent to a neuropathy center with an idiopathic label. After a thorough workup, 93 (32.7%) were still idiopathic. That means about two thirds turned out to have a cause that could be found [1].

That is the whole case for reopening the question. Peripheral nerve disorders affect about 2.4% of the world population and about 8% of older people [2]. The label given at the first visit often just describes how far the workup got.

Key points

• Idiopathic is a statement about the evaluation, not about the nerve.
• Neuropathy is a category, not a diagnosis. The work is finding which cause is active: metabolic, nutritional, autoimmune, toxic or structural.
• Poor sugar handling was the single most common cause found when patients first called idiopathic were checked again [1].
• Nerve conduction studies answer large-fiber questions. A normal study does not rule out small fiber damage.
• Newer testing keeps moving the line. Biallelic RFC1 repeat expansions, a genetic finding, showed up in 2.3% of one large US group with idiopathic neuropathy [3].

What does idiopathic neuropathy mean?

An idiopathic label usually reflects a specific gap. The wrong groups of causes were stressed, the timing of tests was off, or the pattern was never matched to the most useful test. None of those say whether a cause exists.

It is also not a statement about how serious it is. Neuropathy can keep getting worse while the cause goes unmeasured. That is why a stalled workup is worth restarting when symptoms are changing.

How do doctors find the cause of idiopathic neuropathy?

Step one: identify the pattern and the fiber type

Peripheral neuropathy can involve small fibers, large fibers or both. Small fiber damage tends to cause burning pain and changes in temperature or feeling. Large fiber damage more often shows up as numbness, unsteadiness and loss of position sense.

Getting that right early decides which tests are worth running, because the two patterns are answered by different tools.

Step two: connect the pattern to a driver category

A cause is an explanation, in how the body works, for what is going wrong. In practice the work is sorting through overlapping groups. These are metabolic (including poor sugar handling short of diabetes), nutrition and digestion, toxic and environmental, and autoimmune, infectious or structural.

The published recheck data support that focus. Among the 284 patients, poor sugar handling accounted for 72 (25.3%), including 26 with diabetes and 46 with prediabetes. Chronic inflammatory demyelinating polyneuropathy accounted for 57 (20%) and monoclonal gammopathy for 20 (7%). Toxic exposures, Sjögren disease, celiac disease, vitamin B12 deficiency, amyloidosis, vasculitis and inherited causes made up the rest [1]. Those groups are unpacked in the hidden drivers of peripheral neuropathy.

Step three: use testing to answer a question, not to assign a label

We do electrodiagnostic testing (EMG/NCS) on site. It is the right tool for large-fiber questions and for pinpointing a problem. It is a poor tool for confirming small fiber neuropathy, where studies can be normal.

When unsteadiness is part of the picture, we use videonystagmography (VNG) as a test of inner-ear balance. It separates an inner-ear cause from a nerve cause. It is not a treatment.

What hidden causes does an idiopathic neuropathy workup look for?

Metabolic drivers

Sugar handling is the most rewarding place to look, and the published data reflect that. A workup that stops at a normal fasting glucose can miss the poor-sugar-handling group entirely.

Nutritional and digestive drivers

Vitamin B12 deficiency was among the causes found in the recheck series [1]. Absorption matters as much as intake. That is why digestion is part of the nutrition review, not a separate topic.

Toxic and environmental drivers

Medicines, alcohol, work exposures and, less obviously, supplements belong in the history. Too much vitamin B6 is one example of a supplement that can injure nerves instead of protecting them.

Autoimmune and structural drivers

Immune-driven neuropathies made up more than a quarter of the causes found in that series [1]. These include chronic inflammatory demyelinating polyneuropathy and neuropathies tied to monoclonal gammopathy. Worsening, weakness, a lopsided pattern or whole-body symptoms are reasons to widen the workup sooner.

Genetic drivers that were invisible until recently

What testing can find keeps changing what “idiopathic” covers. A US study looked at 788 patients with idiopathic peripheral neuropathy. Biallelic RFC1 AAGGG repeat expansions were found in 18 patients (2.3%), compared with 1 of 778 controls. The yield was highest, at 6.9%, in the group with purely sensory symptoms [3].

Turning findings into a plan

Once the main cause is found, the plan follows it instead of cycling through options. Correcting a nutrient shortage, treating sugar handling and removing a toxic exposure are all cause-level work.

In-clinic therapies sit alongside that, not in place of it. We offer class 4 photobiomodulation, class 3B cold laser and whole-body infrared. Orthobiologic injections (PRP and BMAC) are offered in selected situations.

Qutenza (capsaicin 8% patch) is FDA-approved in adults for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet. It is applied in clinic by a clinician and repeated no more often than every three months.

None of this is a promise of nerve regeneration or reversal. It is a plan matched to what the workup found.

Kidney function is one of the causes a full workup checks. See chronic kidney disease and uremic neuropathy.

Frequently asked questions

Does “idiopathic” mean nothing more can be found?

No. It means the workup that was done did not find a cause. One chart review looked at 284 patients sent to a neuropathy center with an idiopathic label. After a thorough workup, about two thirds were found to have a cause. See small fiber neuropathy symptoms and testing.

Is an EMG and nerve conduction study enough on its own?

It is the right test for large-fiber damage. But nerve conduction studies can be normal when the problem is limited to small fibers. When the symptom pattern points that way, the workup has to go past EMG/NCS instead of stopping at a normal result. We do EMG/NCS on site; see our services and on-site testing.

Which causes are found most often once someone is re-evaluated?

In that same 284-patient review, poor sugar handling was the most common cause. Next came chronic inflammatory demyelinating polyneuropathy and monoclonal gammopathy. Nutrient shortages, including vitamin B12, were among the rest. See functional B12 deficiency and neuropathy.

Can a gut or dietary problem explain nerve symptoms?

It can, in two ways. Poor absorption can lead to nutrient shortages, and the immune system can attack the nerves. Whether it applies to you is an idea to test against your history and labs, not an assumption. See the gluten and neuropathy connection.

Is balance testing a treatment for neuropathy?

No. Videonystagmography (VNG) is a test of inner-ear balance. When someone is unsteady, it helps separate an inner-ear cause from a nerve cause. It does not treat anything. See VNG balance testing.

What is the best treatment for idiopathic neuropathy?

The best treatment is the one aimed at the cause the workup finds. That can mean correcting a nutrient shortage, treating sugar handling, or removing a toxic exposure. In-clinic therapies such as class 4 photobiomodulation, class 3B cold laser, and whole-body infrared sit alongside that work, not in place of it. Qutenza is FDA-approved in adults for nerve pain that lingers after shingles (postherpetic neuralgia) and for diabetic neuropathy of the feet.

Can idiopathic neuropathy be reversed?

No honest clinic promises nerve regeneration or reversal, and Regenerve does not. What matters is that neuropathy can keep getting worse while its cause goes unmeasured. In one review of 284 patients labeled idiopathic, about two thirds turned out to have a cause the workup found. Finding yours gives you something specific to correct. That is the best way to protect the nerves you still have.

What vitamin will repair nerve damage?

No single vitamin repairs nerve damage. Vitamin B12 deficiency is one of the causes found when patients labeled idiopathic are checked again. Absorption matters as much as how much you take in. More is not always better: too much vitamin B6 from supplements can injure nerves instead of protecting them. Bring every supplement you take to your visit so it can be checked as a possible cause.

Next step

If you were told your neuropathy is idiopathic, the next step is a structured look at which cause is doing the most damage right now. Five questions start that map.

Sources

1. Farhad K, Traub R, Ruzhansky KM, Brannagan TH 3rd. Causes of neuropathy in patients referred as “idiopathic neuropathy.” Muscle & Nerve. 2016;53(6):856-861. doi:10.1002/mus.24969. https://pubmed.ncbi.nlm.nih.gov/26561790/
2. Hammi C, Yeung B. Neuropathy. StatPearls. Treasure Island (FL): StatPearls Publishing; last updated October 15, 2022. https://www.ncbi.nlm.nih.gov/books/NBK542220/
3. Tang Z, Ovunc SS, Iwase R, et al. Homozygous RFC1 AAGGG repeat expansions are common in idiopathic peripheral neuropathy. Annals of Neurology. 2026;100(1):95-108. doi:10.1002/ana.78226. https://pubmed.ncbi.nlm.nih.gov/41964406/

The most useful question to ask an insurer is not “do you cover neuropathy testing.” It is “what documentation would support medical necessity for this specific test, for this specific suspected cause, in my case.” Coverage choices turn on whether the record shows a medical reason for the request. Neuropathy is a category, not a diagnosis. So a chart that names only the category gives a reviewer very little to work with.

Key takeaways

• Ask about documentation and medical necessity, not about coverage in the abstract.
• Ask whether the request is for diagnosis or for monitoring, because plans often handle those differently.
• VNG is a test of inner-ear balance. It does not treat neuropathy, and it should not be described to a plan as though it does.
• Qutenza (capsaicin 8% patch) is FDA-approved in adults only for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet [1].
• Plans generally do not cover them.
• We do not publish fees. They are discussed directly with the practice during planning.

How do I talk to my insurance company about a neuropathy test?

Most coverage calls go wrong in the first sentence. The caller describes symptoms, the representative describes a policy, and nobody says what the test is meant to find out.

A clearer opening is to state the purpose. This study is being ordered to confirm or rule out a specific suspected cause of nerve symptoms. That framing is what a reviewer looks for. It is also what a good workup produces anyway.

Questions worth asking word for word

• What documentation would support medical necessity for this test in my case?
• Does the answer change if the study is diagnostic rather than for monitoring?
• Is prior authorization required, and who submits it?
• If this is denied, what specifically would need to be added for an appeal?

Write the answers down with the date and the representative’s name. A prior authorization approval is not a promise of payment. Appeals usually fail on missing paperwork, not on a disagreement about medicine.

Why does the suspected cause of my neuropathy affect coverage?

A request tied to a suspected metabolic cause reads differently from one tied to a suspected nutritional, toxic, autoimmune or structural cause. That is not a billing trick. It is what an honest workup looks like when the clinician has a real idea of the cause.

At Regenerve the order is the same no matter the insurer. Find the likely cause. Choose the test that confirms or rules it out. Then document why. The coverage call is easier because the medical reasoning already exists.

Which neuropathy tests should I ask my insurer about?

Electrodiagnostic testing (EMG/NCS)

We do electrodiagnostic testing on site at Regenerve. It measures conduction in the larger nerve fibers. Maybe your symptoms are burning and temperature change, not numbness and weakness. If so, ask whether the order covers large fibers, small fibers or both. That difference can decide which benefit category applies.

VNG balance testing

Videonystagmography is a test of inner-ear balance. It is used to look into unsteadiness and fall risk. It does not treat neuropathy or anything else. When you call, ask how your plan handles inner-ear (vestibular) tests. That is a separate question from nerve testing. More detail is on our VNG balance testing page.

Does insurance cover Qutenza, PRP, or laser therapy for neuropathy?

Qutenza (capsaicin 8% topical system)

Qutenza is FDA-approved in adults for neuropathic pain associated with postherpetic neuralgia and for neuropathic pain associated with diabetic peripheral neuropathy of the feet [1].

Two other label facts matter for planning. It is administered only by a physician or health care professional and is never dispensed for home use, and it is not repeated more frequently than every three months [1]. Our Qutenza page covers how the application visit works.

Orthobiologic injections (PRP and BMAC)

Plans generally do not cover them.

If this is under discussion, ask for that policy wording in writing before scheduling anything. Expect the answer to be strict.

In-clinic light and infrared therapies

Class 4 photobiomodulation, class 3B cold laser and whole-body infrared are given in clinic as parts of a plan, not as one-time procedures. Ask which benefit category your plan puts office-based therapy in, and what paperwork it expects for each session type.

What we will and will not tell you about cost

We do not publish fees on this site. What a patient owes depends on the plan, the benefits, and what the visit actually includes. A posted number would be wrong for most people reading it.

Fees are discussed directly with the practice during planning.

Frequently asked questions

What should I ask my insurer before neuropathy testing?

Ask what paperwork supports medical necessity for the specific test in your case, not whether neuropathy is covered in general. Then ask whether the answer differs for a diagnostic study versus repeat monitoring, because plans often treat those differently. Knowing which services are on the table first makes that call shorter. So review what we actually provide before you dial.

Why does my chart need to name a driver instead of just saying neuropathy?

Neuropathy is a category, not a diagnosis. So a request that names only the category gives a reviewer nothing to judge against. When the record states the suspected cause and ties the test to confirming or ruling it out, the medical reasoning is visible. See how the Regenerve protocol sequences testing.

Is coverage different for small-fiber evaluation than for EMG?

It can be. Electrodiagnostic testing measures the larger nerve fibers. So when your symptoms point to the small fibers, a different test is needed, and your plan may put it in a different benefit category. Ask which fiber type the order covers. See small fiber neuropathy symptoms and testing.

How do I find out what a visit will cost me?

We do not publish fees, because what applies to you depends on your plan, your benefits and what the visit actually includes. Fees are discussed directly with the practice during planning. Reach us through the Regenerve contact page.

What insurance covers neuropathy?

The better question is what your specific plan needs to see. Coverage usually turns on documented medical necessity: a named suspected cause and a test chosen to confirm or rule it out. A chart that says only “neuropathy” gives a reviewer little to work with. Ask your plan what paperwork supports this test in your case, and whether the study is diagnostic or for monitoring. Then write down the date and the representative’s name.

Is there a test to prove you have neuropathy?

No single test answers every question. EMG and nerve conduction studies, done on site at Regenerve, measure how well the larger nerve fibers conduct. When symptoms point to the small fibers, a different test is needed, and your plan may put it in a different benefit category. VNG is a separate test of inner-ear balance used to look into unsteadiness and fall risk. It does not treat neuropathy.

How can a doctor tell if you have neuropathy in your feet?

It starts with the pattern of your symptoms. Burning and temperature change point to the small nerve fibers. Numbness and weakness point to the larger ones. That pattern decides which test gets ordered. It also shapes how the request is written for your insurer. A test tied to a specific suspected cause, whether metabolic, nutritional, toxic, autoimmune, or structural, makes the medical reasoning clear to a reviewer.

Start with the Nerve Damage Score

The starting point at Regenerve is the free five-question Nerve Damage Score. It takes a few minutes. It tells us which cause to look at first, so your visit starts with a plan instead of a guess.

Take the free Nerve Damage Score assessment. Then bring the result to a physician-led visit at Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport. We see patients from the St. Louis region, Missouri and Illinois.

Sources

1. U.S. Food and Drug Administration. QUTENZA (capsaicin) topical system — Highlights of Prescribing Information, revised 07/2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022395s024lbl.pdf — referenced for the approved indications in adults (postherpetic neuralgia and diabetic peripheral neuropathy of the feet), for administration by a physician or health care professional only, and for repeat application not more frequently than every three months.

Slow stomach emptying can be a sign of autonomic neuropathy, but it is not proof of it. Gastroparesis becomes a nerve question, not a stomach question, when it shows up with other autonomic clues. These include feeling lightheaded on standing, changes in sweating, changes in heart rate, or long-standing diabetes. When those cluster, the useful next step is to find which cause is injuring the nerves, not to treat the stomach alone.

The overlap can be measured. A cross-sectional study looked at 400 Saudi adults with type 2 diabetes at a primary health care center. Cardiovascular autonomic neuropathy was present in 15.3% of them, and gastroparesis symptoms in 6.3% [1].

Key takeaways

• Gastroparesis can reflect autonomic nerve damage, especially in diabetes and other metabolic causes. But it has causes outside the nerves too.
• Neuropathy is a category, not a diagnosis. So the workup looks for the main cause instead of stopping at the label.
• Autonomic and limb nerve symptoms can point to the same underlying process. That is why they are worth mapping together.
• Electrodiagnostic testing checks the nerves in the limbs. Autonomic damage is a separate question that needs its own workup plan.
• Nutrition, medicine, toxic, autoimmune, and structural causes all belong on the list, not only blood sugar.

What is gastroparesis, and how is it linked to the nerves?

Gastroparesis means the stomach empties more slowly than it should, with no physical blockage to explain it. The autonomic nervous system runs functions you do not consciously control. These include heart rate, blood pressure responses, sweating, and how the gut moves food along.

Because gut movement is under autonomic control, injury to autonomic fibers is a plausible route to slow emptying. That is why a digestive symptom can be a nerve clue.

The stomach-only trap

Treating the symptom can quiet the discomfort without touching what is causing it. If an autonomic cause is active, the problem goes on while the symptom is managed.

The other way is to ask which cause is doing the most damage right now. Then choose a workup and care that match that answer.

Why do autonomic neuropathy and gastroparesis occur together in diabetes?

Diabetic nerve injury is not one single process. It combines metabolic and tiny-vessel stresses that can reach several groups of nerves at once, including autonomic fibers.

The same primary care study of 400 Saudi adults with type 2 diabetes found more. Longer disease duration and high blood pressure were independently associated with cardiovascular autonomic neuropathy. Metformin use was an independent predictor of having at least one gastroparesis symptom [1]. When problems show up together like that, clinicians are pushed to think in whole systems, not in silos.

How common is gastroparesis in diabetes?

Less common than symptom questionnaires alone would suggest, and less consistent across studies than a single number implies. A systematic review and meta-analysis of gastroparesis in people with diabetes reported a combined estimated prevalence of 9.3%. It also noted high sensitivity, low robustness, and significant bias factors across the pooled studies [2].

That is a useful warning. Symptom rates, questionnaire-based rates, and coded diagnoses are three different measurements, and they do not agree with each other. It is another reason to weigh your pattern over a label.

What else besides diabetes can cause gastroparesis with nerve symptoms?

Autonomic damage can come with several causes of limb neuropathy, so the question is which one fits your history. These are the patterns we check when gut movement symptoms and nerve symptoms overlap.

Metabolic and nutritional drivers

The metabolic environment around a nerve affects how it signals, through sugar handling, oxidative stress, and fat pathways. Low nutrients belong in the same talk, including B12-related patterns when the history and labs support it.

If burning in the feet at night or dulled feeling is part of your story, that is a reason to review the whole nervous system, not the stomach alone.

Medication and toxin effects

Several medicines slow the gut, and several exposures affect nerve function. When gut and nerve symptoms show up together, it is worth carefully rebuilding the timing of each medicine and your exposure history.

This is also where cases labeled idiopathic often turn out to have an explanation. Unknown often means not yet mapped.

Autoimmune involvement

Immune-driven processes can affect autonomic function in some patients. If your history points that way, it becomes an important piece of the picture, not a footnote.

Gluten-related nerve injury

Not every digestive symptom is a digestive disease. Gluten-related nerve injury can show up as nerve symptoms alongside gut ones. A negative celiac test does not by itself close that question.

How is gastroparesis with nerve symptoms evaluated?

The first goal is to work out which cause is most active and which nerve pathways are involved. That order is what keeps the plan from becoming generic.

Symptom pattern first

The workup looks for clusters that suggest autonomic and limb nerve damage at the same time. Burning, temperature-related discomfort, and other small-fiber features change how the pathway is checked.

The timing of gut symptoms, the full medicine list, and your medical history all feed into that map.

Peripheral testing, including EMG and nerve conduction studies

We do electrodiagnostic testing on site at Regenerve. It checks the nerves in the limbs, mainly the large fibers. It is used to support or refine an idea about the cause, not to settle the autonomic question.

The difference matters both ways. Autonomic symptoms can happen without classic limb nerve findings. And limb nerve findings can point to a body-wide cause affecting more than one nerve system.

Driver-focused care rather than symptom chasing

When gastroparesis and nerve symptoms show up together, the care plan targets what is causing both. Burning feet are usually not a foot problem. And gut symptoms in this setting are usually not only a stomach problem.

For a fuller account of how causes are separated from labels, read about the hidden drivers of peripheral neuropathy.

In-clinic therapies used at Regenerve

For nerve symptom patterns, the plan can include class 4 photobiomodulation, class 3B cold laser, and whole-body infrared. These always go alongside metabolic and nutrition care, guided by a physician’s evaluation. They support the environment around the nerve. They are not a treatment for slow stomach emptying.

Blood flow and nutrient delivery are the base of that work, because a nerve can only repair in an environment that supplies it. For how sugar handling plays into nerve injury, see how glycation damages nerves.

Why this matters for foot symptoms too

Many patients arrive asking about numbness and burning in the feet. Those limb symptoms can point to the same body-wide pathways that affect autonomic function. That is why we check the two together instead of sending them to different doctors.

Frequently asked questions

Can gastroparesis be a sign of autonomic neuropathy?

It can be. In 400 Saudi adults with type 2 diabetes at a primary health care center, cardiovascular autonomic neuropathy was present in 15.3% and gastroparesis symptoms in 6.3%. So the two do show up together in real groups of people. For one person, it comes down to whether other autonomic and nerve clues are present. For more on how metabolic causes are worked up, see diabetic and metabolic drivers of neuropathy.

Is gastroparesis the same thing as diabetic neuropathy?

No. Gastroparesis is slow stomach emptying, while diabetic neuropathy is nerve injury. They can overlap under shared metabolic and tiny-vessel stress, but they are not the same finding. Gastroparesis also has causes that have nothing to do with nerve injury. For the symptom words used to tell fiber types apart, see small fiber neuropathy symptoms and testing.

What testing helps when I have gastroparesis and nerve symptoms?

No single test answers every part of the question. The workup starts with the symptom pattern and history. It can include on-site EMG and nerve conduction studies when limb nerve damage is the question. Autonomic testing is handled separately. For what is available in clinic, see the services offered at Regenerve.

My workup was called idiopathic but I also have gut symptoms. What now?

Idiopathic means the cause has not been found with the testing done so far. It does not mean there is nothing to find. Nutrition, medicine, autoimmune, and toxic causes are all worth a second look when the history supports them. For one often-missed nutrition pattern, see why a normal B12 result can still miss neuropathy.

What are the first signs of autonomic neuropathy?

Autonomic nerves run functions you do not consciously control, so the early clues show up there. They include lightheadedness when you stand, changes in sweating, changes in heart rate, and slow stomach emptying. One clue alone proves little. When several show up together, especially with long-standing diabetes or burning and numbness in the feet, the nerves become the question worth answering.

Can medications cause gastroparesis symptoms?

Yes. Several medicines slow the gut, so the full medicine list and the timing of each drug are part of the workup. In the study of 400 Saudi adults with type 2 diabetes in primary care, metformin use was an independent predictor of having at least one gastroparesis symptom. Exposure history matters for the same reason, because several exposures affect nerve function.

Can an autoimmune problem affect the autonomic nerves?

It can. Immune-driven processes affect autonomic function in some patients. When the history points that way, autoimmune activity becomes an important piece of the picture, not a footnote. It sits on the same list as metabolic, nutrition, medicine, toxic and structural causes. The workup looks for whichever one is doing the most damage.

Can gluten cause both stomach and nerve symptoms?

Gluten-related nerve injury can show up as nerve symptoms alongside gut ones, so not every stomach complaint is a stomach disease. A negative celiac test does not by itself close that question. When gut and nerve symptoms come together, gluten belongs on the list of causes to check, along with B12-related and other nutrition patterns.

Take the next step

If gut and nerve symptoms are showing up together, the useful move is to map the cause instead of guessing. Start with the free five-question Nerve Damage Score. Regenerve is at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport, serving the St. Louis region, Missouri and Illinois. Call (314) 886-5739 or text (314) 886-5902, or email info@regenerve.com.

Sources

1. AlOlaiwi LA, AlHarbi TJ, Tourkmani AM. “Prevalence of cardiovascular autonomic neuropathy and gastroparesis symptoms among patients with type 2 diabetes who attend a primary health care center.” PLoS ONE. 2018;13(12):e0209500. https://pmc.ncbi.nlm.nih.gov/articles/PMC6303088/ (referenced for: 400 adults with type 2 diabetes in Saudi primary care; cardiovascular autonomic neuropathy present in 15.3%; gastroparesis symptoms present in 6.3%; disease duration and hypertension independently associated with CAN; metformin use an independent predictor of at least one gastroparesis symptom).
2. Li L, Wang L, Long R, Song L, Yue R. “Prevalence of gastroparesis in diabetic patients: a systematic review and meta-analysis.” Scientific Reports. 2023;13:14015. https://www.nature.com/articles/s41598-023-41112-6 (referenced for: combined estimated prevalence of gastroparesis in people with diabetes of 9.3%, with high sensitivity, low robustness and significant bias factors noted by the authors).

A second opinion on idiopathic neuropathy is worth getting when the label came from a workup that did not match your symptoms. Idiopathic means the tests done so far did not find the cause. It does not mean no cause exists. The second visit should not hand you a new name for the same problem. It should give you a clear answer. What was tested? What was not? What would change the plan?

That question has room to move. Peripheral neuropathy covers a broad range of clinical pathologies (disease processes) that can show up as peripheral nervous system dysfunction [1]. In a group that wide, an incomplete workup can plausibly stop short.

Key takeaways

• Idiopathic describes the state of the workup, not the state of your nerves.
• Bring the timeline, the labs, and the nerve test reports. A second opinion is only as good as the record it starts from.
• Ask which fiber type your symptoms fit. Small-fiber and large-fiber patterns are checked in different ways, so the answer matters.
• Ask what is still untested, what result would change the plan, and when the case will be looked at again.
• Metabolic, nutritional, autoimmune, toxic, and structural drivers can overlap. More than one can be active at once.
• A useful plan ranks the drivers. It does not just list symptoms.

What does idiopathic neuropathy mean?

When neuropathy is called idiopathic, the honest translation is simple. The tests used so far did not find a cause. It says nothing about the state of the nerve fibers. It says nothing about microcirculation (the tiny blood vessels) or metabolic signaling either.

Small fiber neuropathy is a good example. Up to half of small fiber neuropathy cases are idiopathic. Yet the clinical advice is still to search for an identifiable underlying cause amenable to treatment. Autonomic symptoms (problems with automatic body functions) occur in nearly half of patients with small fiber neuropathy. They can be as troublesome as the neuropathic pain itself [2].

Peripheral neuropathy is a category, and the driver decides the plan

Two people with the same numbness can have different causes behind it. That is why a good second opinion looks at the terrain around the nerve. It does not stop at the feeling you report.

It also means the plan can be concrete before the label changes. Address blood flow in the tiny vessels where it is impaired. Cut metabolic injury where it is relevant. Supply the raw materials (substrates) nerve repair depends on.

What should I bring to a neuropathy second opinion?

Arriving organized shortens the visit and makes it more useful. Gather the following before you go.

• A one-page symptom timeline: when it started, where it started, and what has changed since.
• Your past diagnoses, in the exact words used on the reports.
• All lab results. Include glucose metrics, B12-related testing, thyroid studies, and any metabolic or vitamin panels.
• All nerve test reports, including any EMG and nerve conduction studies.
• A full list of drugs and supplements. Add your chemotherapy history and alcohol history.
• Family history of diabetes, autoimmune disease, or neuropathy.

Note whether your symptoms include burning at night or loss of feeling. Note whether they are the same on both sides (symmetric). The pattern tells us where to search for the driver.

What should a second opinion for neuropathy check?

1. Confirm the symptom pattern and the fiber type involved

Some neuropathies mainly hit small fibers, some large fibers, and some both. Symptoms can be real and disabling even when standard nerve conduction studies do not explain them. Small-fiber patterns cause this most often.

Ask which fiber type your symptoms fit and how that was decided. Burning, tingling, numbness, and autonomic features each carry different weight in that call.

2. Review whether the testing matched the clinical features

Some patients have atypical clinical features. Examples are rapid symptom onset, severe neuromotor impairment, or asymmetrically abnormal sensation (one side worse than the other). For them, neurology consultation and specialized testing are indicated. That includes nerve conduction studies and intraepidermal nerve fiber density testing (a count of nerve fibers in a small skin sample) [1]. If you had any of those features, it is fair to ask if the workup reflected that.

3. Map metabolic, nutritional, autoimmune, toxic, and structural drivers

Neuropathy is rarely explained by blood sugar alone. More than one driver can be active at the same time. A real driver search looks at least at the following.

• Gluten-related nerve injury. A negative celiac test does not by itself rule it out.
• B12-related patterns. That includes functional deficiency, when a serum (blood) level looks fine.
• Chemotherapy exposure, and when it happened compared with when symptoms began.
• Alcohol-related nerve injury and the nutrient loss that comes with it.
• Heavy metals and other toxins you were exposed to.
• Autoimmune causes such as lupus or rheumatoid arthritis.
• Malabsorption (poor uptake of nutrients) after stomach or bowel surgery.
• Structural causes, like a pinched nerve, stacked on top of a whole-body process.

For how these are sorted out in practice, read about the hidden drivers of peripheral neuropathy.

How do I choose a doctor for a neuropathy second opinion?

Choose someone who can answer driver questions, not only symptom questions. The difference shows up in the first ten minutes.

Ask about on-site testing and how decisions get made

Regenerve does electrodiagnostic testing on site. That means EMG and nerve conduction studies. It sits alongside checks of the blood vessel and metabolic terrain around the nerve. Ask any clinic what they can do in-house. Ask what a given result would change.

For what to look for and what to ask, see choosing a neuropathy specialist in St. Louis.

Ask how they handle idiopathic cases specifically

The useful answer describes a process. What is checked when the standard workup finds nothing? How do they choose between electrodiagnostic testing and another route? When does the case get looked at again?

Say the answer is a prescription and a follow-up in six months, with no re-exam planned. That is worth knowing before you book.

Which neuropathy treatments will I hear about, and how should I judge them?

Neuropathy is a heavily marketed field. Your defense is to ask for a driver-first account of what is being treated and why.

Light-based and infrared therapies

Class 4 photobiomodulation, class 3B cold laser, and whole-body infrared are used at Regenerve. They are part of a physician-directed plan, alongside metabolic and nutritional care. Ask any clinic offering them where they fit next to the driver found by testing. They should not be sold as a standalone package.

Qutenza needs the correct indication and clear expectations

Qutenza, the capsaicin 8% patch, is FDA-approved in adults for neuropathic pain associated with postherpetic neuralgia and with diabetic peripheral neuropathy of the feet.

A clinician applies it in the clinic. It is never sent home with you. It is repeated no more often than every three months.

Orthobiologic injections at Regenerve

Regenerve offers platelet-rich plasma and bone marrow aspirate concentrate injections. Any clinic that sells them as established treatment for nerve damage is overstating what is known.

Frequently asked questions

Is idiopathic neuropathy the same as nothing can be done?

No. Idiopathic describes what the completed workup found. A second opinion can re-map the driver. This matters most when the symptom pattern suggests small-fiber involvement, which standard testing does not catch well. The plan can also work on the terrain around the nerve while the driver search goes on. For what those symptoms look like, see small fiber neuropathy symptoms and testing.

Can a negative celiac test rule out gluten-related nerve injury?

Not on its own. Gluten-related nerve injury can cause nerve symptoms in patients whose standard celiac testing is negative. So a single result should not close the question when the history points that way. Ask which tests were run and what they do and do not rule out. For the fuller picture, see the gluten and neuropathy connection.

My B12 was normal. Can B12 still be part of this?

It can. A serum B12 level in the normal range does not always reflect how B12 is working in the tissues. That is why a normal result alone is not a reason to drop the question. Ask whether functional markers were checked. For how that testing works, see why a normal B12 result can still miss neuropathy.

Diabetes was never confirmed as my cause. Is a second opinion still useful?

Yes, because metabolic injury can contribute without a formal diabetes diagnosis. Glucose handling sits on a spectrum, not a switch. A second opinion can show whether metabolic drivers belong in your plan at all. For how that work is done, see diabetic peripheral neuropathy treatment in St. Louis.

Can you reverse idiopathic neuropathy?

No one can honestly promise that. The label itself does not answer the question. Idiopathic only means the tests done so far did not find a cause. A second opinion looks for the driver behind the nerve damage: metabolic, nutritional, autoimmune, toxic, or structural. Once a driver is named, the plan can target it. That means better blood supply to the nerve, less metabolic injury, and supplying what nerve repair depends on.

What are the symptoms of idiopathic neuropathy in the feet?

They include burning, tingling, and numbness. Some people also have autonomic symptoms. In small fiber neuropathy, autonomic symptoms show up in nearly half of patients. They can be as troublesome as the pain itself. Before your visit, note whether you have burning at night or loss of feeling. Note whether both sides are affected the same way. That pattern tells the doctor where to look for a cause.

What is the newest treatment for neuropathy in your feet?

Newer is not the same as right for you. At Regenerve, options include class 4 photobiomodulation, class 3B cold laser, and whole-body infrared. They are used inside a physician-directed plan with metabolic and nutritional care. Qutenza, the capsaicin 8% patch, is FDA-approved in adults for nerve pain from diabetic neuropathy of the feet. A clinician applies it in the clinic, no more often than every three months. Ask how any treatment fits the cause your testing found.

Take the next step

If idiopathic ended your last conversation instead of starting the next one, a structured driver search is the way forward. Begin with the free five-question Nerve Damage Score. Regenerve is at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport. We serve the St. Louis region, Missouri and Illinois. Call (314) 886-5739 or text (314) 886-5902, or email info@regenerve.com.

Sources

1. Bodman MA, Dreyer MA, Varacallo MA. “Diabetic Peripheral Neuropathy.” StatPearls. StatPearls Publishing; last updated February 25, 2024. https://www.ncbi.nlm.nih.gov/books/NBK442009/ (referenced for: peripheral neuropathy encompasses a broad range of clinical pathologies presenting with peripheral nervous system dysfunction; neurology consultation and specialized testing including nerve conduction studies and intraepidermal nerve fiber density testing are indicated for atypical clinical features such as rapid symptom onset, severe neuromotor impairment, and asymmetrically abnormal sensation).
2. Tavee JO. “Office approach to small fiber neuropathy.” Cleveland Clinic Journal of Medicine. 2018;85(10):801–812. https://www.ccjm.org/content/85/10/801 (referenced for: up to half of small fiber neuropathy cases are idiopathic and a search for a treatable underlying cause is still indicated; autonomic symptoms occur in nearly half of patients with small fiber neuropathy and can be as troublesome as neuropathic pain).
3. Averitas Pharma Inc. “QUTENZA (capsaicin) 8% topical system — prescribing information.” U.S. National Library of Medicine, DailyMed; label revised July 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ffbbcb0-ad93-4f15-bb38-5da76a71c735 (referenced for: indicated in adults for neuropathic pain associated with postherpetic neuralgia and for neuropathic pain associated with diabetic peripheral neuropathy of the feet; only physicians or health care professionals are to administer it; may be repeated not more frequently than every three months).

Peripheral neuropathy disrupts sleep because its pain tends to get worse at night. Broken sleep then makes the pain harder to tolerate. In diabetic peripheral neuropathy, the pain has been described as superficial, deep-seated, or severe, unremitting pain that flares at night [1]. What helps is treating both halves of that loop. Find and address the driver behind the nerve injury. And stop the nights from feeding the next day’s symptoms.

The loop is not a metaphor. Nerve pain (neuropathic pain) and poor sleep make each other worse. There is evidence that broken sleep may help turn short-term nerve pain into chronic nerve pain [2].

Key takeaways

• Nighttime worsening is a known feature of nerve pain. It is not a sign that you are imagining it.
• Sleep loss and pain feed each other, so a plan that addresses only one of them tends to stall.
• Neuropathy is a category, not a diagnosis. So the first move is finding which driver is active.
• Burning, tingling, and numbness can each disturb sleep in different ways. Each can point to different nerve fibers being involved.
• Electrodiagnostic testing shows nerve involvement and its pattern. It does not measure sleep.
• No treatment offered here reverses nerve damage. And none is promoted with an outcome percentage.

Why does nerve pain feel worse when you lie down at night?

Symptoms do not clock out at bedtime. Many people notice that burning, electric jolts, tingling, and aching build through the evening. Going to bed then means lying still with an alarm that will not switch off.

Peripheral neuropathy commonly causes numbness, tingling, aching, and burning. It also causes hyperalgesia (extra pain from things that should hurt a little) and allodynia (pain from things that should not hurt at all) [1]. When skin and nerves are on high alert, normal background feelings register as heat or pain. And lying still takes away the distraction that daytime movement gives you.

What the sleep-pain loop does

Poor sleep here is not only a result. Pain makes it hard to fall asleep and stay asleep. The broken sleep then feeds back into the pain problem instead of easing along with it [2].

That is why bedtime routine advice alone rarely settles a night of nerve pain. The cause of the symptom has to be addressed as well.

Which neuropathy symptoms keep you awake at night?

Nighttime complaints tend to cluster. Some people describe a flare as they settle in. Others sleep for a few hours and then wake up to burning, or to discomfort they cannot shift away from.

• Burning: hot-coal feelings and skin irritation that grow stronger once you stop moving.
• Reduced sensation: losing the feeling that protects you makes a comfortable position harder to find. It also makes you more aware of pressure.
• Tingling and electric pain: nerves firing when they should not. It keeps you from settling even when medication takes the edge off.

Many people also describe a length-dependent pattern. It starts in the toes and moves upward over time. That pattern points toward whole-body (systemic) drivers, not a local foot problem.

What causes the nerve pain that wakes you up?

Peripheral neuropathy covers a broad range of disease processes [1]. So different causes can drive the night alarm in different people. Metabolic stress and low nutrients are on the list. So are toxins, autoimmune disease or infection, and structural compression (nerves being pinched).

Maybe you have been told it is neuropathy with no account of the cause. Then you are left with volume control, not a plan. The evaluation at Regenerve starts by finding which driver is doing the most damage now.

Metabolic drivers and the glycation pathway

Glycation (sugar sticking to proteins) and advanced glycation end-products are part of how metabolic stress injures nerves. That pathway can matter even when routine labs look fine. We read symptoms, labs, and metabolic pattern together, not one marker at a time.

Nutritional and immune drivers

Gluten-related nerve injury can keep nerves on high alert in some patients whose standard celiac testing is negative. B12-related patterns are similar. A blood level inside the normal range does not always show how B12 is working in the tissue.

Small-fiber patterns

Small fiber involvement is especially disruptive at night. It produces burning and hot feelings that seem skin-deep, and they are hardest to ignore when you are lying still. For the symptom language and how it is tested, see small fiber neuropathy symptoms and testing.

Can a nerve test show why neuropathy disrupts my sleep?

Electrodiagnostic testing, meaning EMG and nerve conduction studies, is done on site at Regenerve. It helps confirm nerve involvement and its pattern, especially in the large fibers. It is most useful when there is weakness. It also helps when the pattern points to one specific nerve or root.

It does not measure sleep, and it does not capture small-fiber involvement well. VNG is also done on site. But it is a diagnostic test of inner-ear balance function. It is not a treatment for neuropathy or for sleep.

What is used in clinic, and what it is for

Regenerve uses class 4 photobiomodulation, class 3B cold laser, and whole-body infrared. These go with metabolic and nutritional care, guided by a doctor’s exam. They are aimed at the area around the nerve. They are used as part of a plan, not as a package sold on their own.

Two other options are worth knowing. Qutenza, the capsaicin 8% patch, is FDA-approved in adults only for neuropathic pain associated with postherpetic neuralgia and with diabetic peripheral neuropathy of the feet. A clinician applies it in the clinic. It is never handed out for home use. It is repeated no more often than every three months [3].

Orthobiologic injections are offered here. These are platelet-rich plasma and bone marrow aspirate concentrate.

What none of this claims

Nerve tissue heals slowly, if it heals at all. Nothing on this list is offered as a way to regenerate, reverse, or eliminate nerve damage. For how the pieces are put in order, see the Regenerve protocol for peripheral neuropathy.

What can I do when neuropathy keeps me up at night?

Next to the medical plan, a few habits turn the nights from a mystery into something you can track.

• Map the nights: note when burning and waking spike. Note what positions, bedding, footwear, and evening activities change them.
• Bring the list: medications, supplements, alcohol, and exposures. Several of them are drivers in their own right.
• Protect the feet during the day: with less feeling, a daytime injury can show up as nighttime symptoms.
• Raise sleep directly: if the nights are the worst part, say so. It changes what gets priority.

Frequently asked questions

Why does neuropathy get worse at night?

Night flares are a known feature of the nerve pain in diabetic peripheral neuropathy. Lying still takes away the daytime input that competes with the symptom. Broken sleep then makes the next night harder, not easier. For what actually helps in feet-first neuropathy, see peripheral neuropathy treatments for the feet.

Will treating my blood sugar fix the nighttime burning?

It can help if metabolic stress is the main driver. But blood sugar alone rarely explains neuropathy, and more than one driver can be active at once. That is why the evaluation looks at the whole picture, not one number. For how metabolic injury reaches the nerve, see how glycation damages nerves.

My nerve pain started after shingles. Is that the same problem?

The cause is different, and so is the treatment path. Postherpetic nerve pain has its own pattern and its own approved options. It is worth naming on its own, not folding into a general neuropathy plan. For that pattern, see postherpetic neuralgia and shingles nerve pain.

Can in-clinic light or infrared therapy fix my sleep?

They are used to support the area around the nerve. They are not a sleep treatment. They are not offered with any promise of nerve regeneration or reversal. Sleep tends to get better when the driver underneath is addressed and night symptoms settle. For what is available and how it is used, see the services offered at Regenerve.

What is the best thing for neuropathy at night?

Treat both halves of the loop. Pain breaks sleep, and broken sleep makes the pain harder to bear. So a plan that fixes only one side tends to stall. Start by finding the driver behind the nerve injury, because bedtime routines alone rarely settle nights of nerve pain. Meanwhile, track when burning and waking spike and what changes them. Protect your feet during the day. And tell your doctor if the nights are the worst part.

Can neuropathy be reversed?

Nerve tissue heals slowly, if it heals at all. Nothing Regenerve offers is presented as a way to regenerate, reverse, or erase nerve damage. That includes light and infrared therapy, Qutenza, and orthobiologic injections. The real goal is to find and address the driver doing the most damage now. It may be metabolic, nutritional, toxic, autoimmune, or structural. The other goal is to calm the nighttime symptoms that keep feeding the pain.

What are the worst symptoms of peripheral neuropathy?

For many people, the worst are the ones that show up at night. Burning can feel like hot coals once you stop moving. Numbness makes a comfortable position hard to find. Tingling and electric pain keep you from settling even when medication takes the edge off. When skin and nerves are on high alert, ordinary sensations register as heat or pain. Symptoms that start in the toes and climb upward point toward a whole-body driver, not a foot problem.

Take the next step

If neuropathy is taking your nights, the first move is finding the driver, not adding another bedtime remedy. Start with the free five-question Nerve Damage Score. Regenerve is at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport. It serves the St. Louis region, Missouri and Illinois. Call (314) 886-5739 or text (314) 886-5902, or email info@regenerve.com.

Sources

1. Bodman MA, Dreyer MA, Varacallo MA. “Diabetic Peripheral Neuropathy.” StatPearls. StatPearls Publishing; last updated February 25, 2024. https://www.ncbi.nlm.nih.gov/books/NBK442009/ (referenced for: neuropathic pain in diabetic peripheral neuropathy characterized as superficial, deep-seated, or severe, unremitting pain with exacerbation at night; symptom components including numbness, tingling, burning, hyperalgesia and allodynia; peripheral neuropathy encompasses a broad range of clinical pathologies).
2. Ho A, Drew VJ, Kim T. “What Links Sleep and Neuropathic Pain? A Literature Review on the Neural Circuits for Sleep and Pain Control.” Nature and Science of Sleep. 2025;17:813–838. doi:10.2147/NSS.S509013. https://pmc.ncbi.nlm.nih.gov/articles/PMC12065536/ (referenced for: neuropathic pain significantly disrupts sleep, creating a feedback loop in which pain and sleep disturbance exacerbate each other; evidence that sleep disruption may contribute to progression from acute to chronic neuropathic pain).
3. Averitas Pharma Inc. “QUTENZA (capsaicin) 8% topical system — prescribing information.” U.S. National Library of Medicine, DailyMed; label revised July 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ffbbcb0-ad93-4f15-bb38-5da76a71c735 (referenced for: indicated in adults for neuropathic pain associated with postherpetic neuralgia and for neuropathic pain associated with diabetic peripheral neuropathy of the feet; only physicians or health care professionals are to administer it; may be repeated not more frequently than every three months).

Both drugs have randomized trial evidence for nerve pain. A 2025 systematic review and meta-analysis in Frontiers in Pain Research compared them. Pregabalin produced greater improvement in pain scores than gabapentin from four weeks onward, through 12 to 14 weeks of follow-up [1]. The same review found no significant difference between the two in dizziness or sleepiness. But gabapentin showed more nausea and vomiting [1]. What the evidence does not support is treating either drug as an answer to the injury that is making the pain signal.

Nerve pain is common enough that the question comes up all the time. Its rate in the general population is estimated at 3.2% to 10.3% [1]. People across the St. Louis region, Missouri and Illinois ask us the same thing. Are these medicines worth taking, and what else should be happening at the same time?

Key points

• Gabapentin and pregabalin are gabapentinoids. They act on pain signaling. They do not correct the metabolic, nutritional, autoimmune, toxic or structural cause behind the injury.
• Head-to-head trial evidence favors pregabalin on pain intensity and on patient-reported quality of life over 12 to 14 weeks [1].
• Dizziness and sleepiness are the side effects most often reported for both. They are also the most common reasons people stop [2].
• Neuropathy is a category, not a diagnosis. The cause decides what else belongs in the plan.
• Start by finding which cause is doing the most damage. Then decide what role, if any, a gabapentinoid should play.

Is pregabalin better than gabapentin for nerve pain?

Pain intensity

The 2025 meta-analysis pooled randomized trials that compared the two drugs directly in nerve pain. Pregabalin showed significantly greater pain improvement than gabapentin at four weeks and onward. Most main comparisons fell at 12 to 14 weeks of follow-up [1].

A better average in pooled trial data is not a promise about your result. It tells you which drug is more likely to help. It does not tell you whether the cause of your symptoms is being treated.

Quality of life and function

The same review reported significantly greater improvement in general quality-of-life scores for pregabalin compared with gabapentin [1]. When burning feet disrupt sleep, a change in daily function can matter more than a change in one pain score.

We also look at what else a patient takes for pain, because the goal is to cut the overall load, not add another prescription to it.

What are the side effects of gabapentin and pregabalin?

Tolerability drives whether people keep taking a drug. In nerve pain trials, dizziness and sleepiness were the side effects reported most often for both pregabalin and gabapentin compared with placebo. They were also the most common reasons for stopping either medicine [2].

Are gabapentin and pregabalin riskier for older adults?

Dizziness and sleepiness raise fall risk and dull daytime activity. Before starting or raising a gabapentinoid, the review should cover other sedating medicines, alcohol use and the conditions that make those effects stronger.

Stopping matters too. As of June 2020, New Zealand’s Centre for Adverse Reactions Monitoring had received seven reports of withdrawal syndrome for pregabalin and seven for gabapentin [2]. Changes should be planned with the prescriber, not made suddenly.

Do gabapentin and pregabalin treat the cause of neuropathy?

Neuropathy is a category, not a diagnosis

Burning, numbness and electric feelings describe how damaged nerves misfire. They do not tell you what is damaging them. Metabolic injury, nutrient shortage, autoimmune attack, toxic exposure and pinched nerves all cause overlapping symptoms.

That is why we treat the terrain around the nerve, not only the signal coming off it. A gabapentinoid can quiet the alarm while the emergency goes on.

Where testing fits

We do electrodiagnostic testing (EMG/NCS) on site. It helps map large-fiber damage. When the pattern suggests small fiber neuropathy, standard nerve conduction studies can be normal. So the workup has to go beyond them.

Balance complaints are checked separately with videonystagmography (VNG), a test of inner-ear balance. It is not a treatment.

What sits alongside gabapentinoids in our plans

Qutenza (capsaicin 8% patch)

Qutenza is FDA-approved in adults for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet. It is applied in clinic by a clinician, is never dispensed for home use, and is repeated no more often than every three months.

In-clinic light and laser therapies

We also offer class 4 photobiomodulation, class 3B cold laser and whole-body infrared. These are part of a cause-based plan. They do not replace finding what is injuring the nerve.

Orthobiologic injections (PRP and BMAC) are offered in selected situations. The framework behind all of it is in the Regenerve Protocol for peripheral neuropathy.

Duloxetine is the other first-line pill for burning feet. Its trial results and limits are covered in duloxetine for painful diabetic neuropathy.

Frequently asked questions

Does pregabalin work better than gabapentin for neuropathic pain?

A 2025 systematic review and meta-analysis of randomized trials compared them. Pregabalin produced greater improvement in pain scores than gabapentin from four weeks onward through 12 to 14 weeks of follow-up. That is an average across trial groups, not a prediction for one person. That is why we map the cause first. See the hidden drivers of peripheral neuropathy.

What side effects do people notice first?

In nerve pain trials, dizziness and sleepiness were the side effects reported most often for both pregabalin and gabapentin compared with placebo. They were also the most common reasons people stopped treatment. In older adults those effects can affect balance and daytime function, so they are worth reviewing at every visit. See small fiber neuropathy symptoms and testing.

Is there a non-oral option for burning feet?

Qutenza (capsaicin 8% patch) is FDA-approved in adults for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet. It is applied in clinic by a clinician, never dispensed for home use, and repeated no more often than every three months. See Qutenza (capsaicin 8% patch).

Should I have nerve testing before starting a gabapentinoid?

Electrodiagnostic testing (EMG/NCS) helps show whether the pattern fits a large-fiber neuropathy and where the problem sits. It tells you less when the symptoms point to small fiber damage. So the testing plan should follow the symptom pattern. We do EMG/NCS on site; see our services and on-site testing.

Can I stop gabapentin or pregabalin on my own?

No. Withdrawal reactions have been reported to national drug-safety monitoring for both medicines. So any change should be planned with the prescriber, not made suddenly. Symptom control and work on the cause usually need to be adjusted together. See peripheral neuropathy treatments for the feet.

Is it okay to switch from gabapentin to pregabalin?

A switch can make sense, but plan it with your prescriber instead of doing it on your own. In pooled trials, pregabalin improved pain scores and quality of life more than gabapentin over 12 to 14 weeks. Withdrawal reactions have been reported for both medicines, so neither should be stopped suddenly. And the change should fit a plan aimed at the cause.

Which is safer, gabapentin or pregabalin?

Their safety profiles are close. The 2025 meta-analysis found no significant difference between them in dizziness or sleepiness, though gabapentin showed more nausea and vomiting. Dizziness and sleepiness are also the most common reasons people stop either drug. Withdrawal reactions have been reported for both. In older adults, those effects raise the risk of falls.

What other treatments are used alongside gabapentin or pregabalin?

At Regenerve, a gabapentinoid is one piece of a cause-based plan, not the whole plan. Alongside it we may use Qutenza (capsaicin 8% patch) for diabetic nerve pain in the feet, class 4 photobiomodulation, class 3B cold laser and whole-body infrared. In selected situations we may add PRP or BMAC injections. The first job is finding which cause is injuring the nerve.

Next step

Five questions show which cause is doing the most damage right now. Start there. Then decide what role gabapentin or pregabalin should play in your plan.

Sources

1. Mayoral V, et al. Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety. Frontiers in Pain Research (Lausanne). 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11747324/
2. Medsafe (New Zealand Medicines and Medical Devices Safety Authority). Spotlight on gabapentin and pregabalin for neuropathic pain. Prescriber Update 42(1):3, 4 March 2021. https://www.medsafe.govt.nz/profs/PUArticles/March2021/Spotlight-on-gabapentin-and-pregabalin-for-neuropathic-pain.html